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ABSTRACT
Effects of Antiepileptic Drugs on Immune Function
in Human Subjects and Mice
by
Nadine C. Margaretten, Doctor of Philosophy
Utah State University, 1985
Major Professor: Dr. Reed P. Warren
Department: Interdepartmental Program in Tox icology
A number of

immune abnormalities have been found

patients treated with antiepileptic drugs (AED).
range from mild suppression of immunoglobulins
humoral

and

cellular immunities.

in

epileptic

The alterations seen
to

severly

impaired

There is evidence for both drug

effects and genetic or acquired factors as contributors to these abnermalities.

In order to examine the basis for immune

abnormalties

in

patients with epilepsy, a number of experimental designs were employed:
clinical stud ies, in vitro studies, and use of an animal model.
Periphera l

blood mononuclear cells (PBMC) isolated from epileptic

patients currently
OKT4+/0KT8+

receiving AED were found

ratio.

to

have a

reduced

A reduced natura l killer (NK) cell activity was

found which may be due to a low proportion of Leu 11+ cel l s.

A reduced

NK ce l l activity was also found in healthy siblings of the patients,
indicating

a possible genetic basis for the level of this

Antibody-dependent
respo nses,

and

cell-mediated

total

cytotoxicity

rosette-forming

patieots were found to be normal.

cells of

{ADCC),
PBMC

activity.
mitogenic

isolated from

The AED

function alterations and lymphoma.
to depress

In this study,

phenytoin was found

basal and augmented NK cell activity of human cells

dose-dependent manner

in

vitro.

This

depression was

following

short-term exposure and at levels

Phenytoin

also depressed ADCC,

alters

ix
immune

phenytoin has been associated with a variety of

immune

cytotoxicity.

function

is

its

a

reversible

considered therapeutic.

thus one mechanism by which
by

in

depression

of

phenytoin

cell -mediated

In contrast to results obtained with phenytoin, the AED

carbamazep ine did not significantly alter NK cell

activity,

but the

diluent propylene glycol depressed activity.
NFS mice given phenytoin produced lower spec ifi c antibody titers
fo ll owing antigen challenge.
thymus,
mice.
dosages

sp l een,
The

Body weights, specific organ weights for

and liver, and blood cell counts were normal in these

protocol

was well tolerated by the animals

ranging from therapeutic to

neurotoxic.

at phenytoin

Susceptibility to

murine hepatitis virus was found to be increased in mice given a high
dose of phenytoin.

Thi s animal model should allow investigations

into

toxic dose levels and mechanisms by which phenytoin and other AED alter
immune function.
(10~

pages)

CHAPTER I
INTRODUCTION
The epilepsies are
disorders

having

in

(seizures)

episodes

a group of chronic

central

common the occurence of

system

sudden and transitory

of abnormal phenomenon of motor

sensory, autonomic, or psychic origin.

nervous

(convulsions),

Seizures are usually correlated

abnormal and excessive electroencephalogram discharges (Rail

with

Schleifer,

1980).

and

The occurence of epilepsy in the general population

is between 3 and 6 per 1000 people (Hauser,

1978).

There are approxi-

mately twenty two thousand patients with epilepsy in the state of

Utah

and

with

two million in the United States.

epilepsy

on a long term basis.
is

to

suppress

minimum.

The majority of patients

receive antiepileptic medication for the control of

seizures

The object in the treatment of seizure disorders

seizure activity while keeping

Often this is a difficult ideal to

side effects at

a

achieve due to the nat ure

of the disorder and the treatment regimen itself; that is by definition
epilepsy

is a chronic condition and treatment is long-term.

Multiple

therapy is often necessary due to the presence of more than one seizure
type in a patient. Other factors are thought to contribute to long-term
side effects of antiepileptic drugs:
young

age,

periods of acute toxicity,

these include treatment at
and the

presence of other

conditions suc h as mental retardation.
Many of

the toxicities associated with the

long-term

use of

antiepileptic drugs have recently been reviewed including their effects
on

the

immune system

(Oxley et al 1983).

There appears

to

be a

different individual susceptibility to the immunosuppressive effects of

being

2
unaffected.

individuals may be dramatically affected however,

and display

antiepileptic
Certain

drugs

with the majority of patients

complex immunodeficiencies as either a primary or secondary reaction to
a drug or combination of drugs.
found

Patients on multiple therapy have been

to have decreases in specific antibody titers and

frequency of respiratory infections.
commonly

used

antiepileptic drug

increases

in

Long-term use of phenytoin,
(AED),

has

been most

a

notably

associated with decreases in IgA but both humoral and cellular immunity
can be affected and to a significant degree.
The intent of this

study was to further the understanding of how

the immune system is affected by AED.

Three approaches were employed:

clinical studies, in vitro studies, and use of an animal model.

In the

clinical studies, peripheral blood mononuclear ce ll s were isolated from
patients currently receiving AED to determine any long-term effects by
these drugs

on function and relative

siblings were also

numbers.

Cells from

studied as a means to assess a genetic

healthy
role

in

immune function.
Epilepsy itself has been found to be associated with immune system
abnormalities in some cases.

In order to investigate effects of AED on

certain

lymphocyte activities without the complication of epilepsy,

several

in

donors.

vitro studies were done using cells isolated from

healthy

The AED phenytoin and carbamazepine were studied for

effects

on killer cell activities.
A murine model

to study effects of AED on immune function

was

developed to bypass the complications and limitations of clinical

and

in

vitro studies.

Mice were given phenytoin lo ng-term in studies of

immune responses which represent a cooperation of different cell

types

3

within the immune system. The effects of phenytoin on specific antibody
production and susceptibility to murine hepatitis virus infection were
ascertai ned.

4

CHAPTER II
REVIEW OF THE LITERATURE
Descrjptjon Qf

~

Epileptic
the brain.
allows

attacks have been described as electrical explosions of

In the normal brain, a balance of excitation and inhibition

relevant

information to

be processed while preventing an

overload of information and uncontro l led neuronal
(EEG)

encephalogram

studies

activity .

have indicated that there i s usually

or general area which is the source of epileptogenic

focus

Electroa

activity.

These foci are inherentl y more excitable , and discharge more frequently
than normal.

If not hel d in check by sufficient inhibitory mechanisms,

the excitation

spreads from the focus to nearby

normal

tissue.

A

seizure then occurs, the manifestations of which are dependent upon the
extent of spread of excitation and the anatomical location of the
activity area
system, etc.)

(motor areas,

sensory areas,

hig h

or reticular activating

It is thought that a seizure is maintained by a positive

feedback mechanism of neurons and that several factors come into
to stop an epileptic attack.

play

These include post-synaptic inhibition by

hyperactive neurons, active inhibition by areas of the brain outside of
the

seizure focus,

and local metabolic changes in the

seizure focus

such as depletion of high energy substrates and a buildup of metabolic
waste products (Rail and Schleifer, 1980, Guyton, 1981).
Seizures
history,
lesion,

in a patient are categorized

a neurological exam,
find

the etiology,

after a careful

case

and an EEG in an effort to localize the
and initiate the

correct therapy.

The

importance of correct diagnosis of seizure type lies in the therapy.

5

Various AED are useful in controlling different types of seizures.

A

proper match of drug with seizure type will likely reduce or abolish
seizures.
The
main

International Classsification of Epileptic Seizures
classes

of

seizures:

(bilateral/symmetrical) (Gastaut,
divided

focal
1970).

into those with elementary

(partial)

lists

and

2

general

Partial seizures are further

(cortical

focal)

and

complex

(temporal lobe and psychomotor) symptomatology .
Characteristics of partial seizu res include localized convulsions
or sensory disturbances,
impairment

of

abnormalities.

Focal

or functional

lesions
destroyed

and for the latter,

confused behavior with

consciousness and anterior temporal
epilepsy is usually a result of
abnormalities,

area of the brain,

lobe
local

focal
organic

such as a scar or tumor,

a

or congenitally abnormal circuits in the

brain.

It can involve almost any part of the brain,

either localized

regions

of the cortex or deeper structures of the cerebrum or brain
These brain lesions promote rap id discharges in local

stem.

A discharge
synchronous

neurons.

rate greater than 1000 per second results in a spread of
waves over adjacent cortical

regions.

The waves

are

presumably from localized reverberating circuits that gradually recruit
adjacent

areas

of the cortex into the discharge zone.

excitation wave spreads over the motor cortex,

When

an

a progressive march

of

contractions occurs on the opposite side of the body,
at the mouth and progressing toward the legs.
the opposite direction,
can

usually starting

If the progression is in

the name Jacksonian is used.

A focal attack

be either confined to a specific area of the brain,

signals

from the focus can excite the mesencephalic

or if

strong

portion of the

6

reticular

activating

Manifestations of
amnesia,

system,

a grand

psychomotor seizures

mal

can

include a short

a moment of incoherent speech,

an attack of

anxiety or fear, or a moment of motor activity.
characteristically

attack

occu r.

period of

rage,

sudden

These types of attacks

involve a part of the limbic portion of the brain

(Guyton, 1981 ).
Generalized seizures
The

are divided into

classifications.

several

absence or petit mal seizures are characterized by

abrupt

loss of consciousness associated with

high-voltage,

synch ronous, 3/second spike and wave pattern in an EEG.
are thought

a brief and
bilateral

These seizures

to involve the thalamocortical portion of the reticular

activating system. Attacks usually last between 3 and 30 seconds during
which

time the patient i s unconscious and twitchlike contractions of

muscles,

usually

in the head region (such as

eye

blinking)

Return to consciousness and resumption of activities follows

occur.
(Guyton;

1981).
Tonic-clonic or grand mal se izures are major convulsions with
extreme neuronal discharges in all areas of the brain; cortex, cerebrum
and

the reticular activating system.

the

reticular formation into the spinal cord resulting in generalized

'tonic convulsions'

of the entire

(alternating muscular contractions)
attack.
and

Discharges are transmitted from

body.

Tonic-clonic convulsions

follow toward the end

This type of seizure lasts for a few seconds to many minutes

is followed by a severe fatigue lasting for several hours

prolonged depression of all central nervous system functions.
taken

of the

during

a grand mal seizure reveals

discharges over the entire cortex,

high

voltage,

with
The EEG

synchronous

with both sides of the brain giving

the

7
normal

same type of discharge with the periodicity like that of

alpha

waves.

sync hronous

It

is thought that a grand mal seizure is caused from

discharges from the reticular activating system via

reverberating circuits,
reticular
Guyton,

or reverberation back and forth

local

between the

activating system and the cortex (Rail and Schleifer,

1980;

1981).

Bilateral massive epileptic myoclonus seizures are isolated clonic
jerks

associated with

Infantile
leading

brief bursts of multiple spikes in the EEG.

spasms are a progressive disorder with
to mental

deterioration.

chi ldren

and

muscles,

loss of consciousness,

Atonic

are characterized

complete

spasms

in young

are associated with rythmic clonic contractions of all
and marked autonomic manifestations.

seizures are associated with loss of

se i zures

convulsive

Clonic seizures occur

by

relaxation of all

postural

tone.

Akinetic

impairment of consciousness
musculature,

and

secondary to excessive

inhibitory discharge (Gastaut, 1970).
A certain percentage of seizure disorders appears to be genetic in
origin .

However, most seizures are a result of acquired nervous system

lesions,

either at the time of birth or afterwards.

Primary or idio-

pathic epilepsy denotes cases where no cause of the seizures

can

identified,

various

conditions

whereas with

secondary or symptomatic epilepsy

are thought to contribute to the etiology.

include congenitally malformed circuits in the
other space-occupying lesions,
cerebrovascular
infarctions

changes

head trauma,

These factors

brain,

neoplasm and

hydrocephalus, hematomas,

subsequent to childhood

from various causes .

be

infection,

and

Damage to neurons from a variety of

sources can cause a epileptic foci to develop.

Other conditions which

8

by themselves

do not normally cause epileptic

seizures

in

normal

neuronal tissue can precipitate or potentiate an epileptic attack given
an excitable focus.
gas

concentrations

These conditions include abnormal pH, osmolarity,
(0 ,

CO ) or glucose

2

certain drugs,
metabolic

blood

diseases,

concentrations

in

blood,

2

pressure changes,

certain mental

or other stressor factors (Rail

states

and

and

Schleifer,

Fever, loud noises, or flashing lights may elicit a seizure in

1980).

patients

with

a hereditary predisposition

to grand mal

attacks

(Guyton, 1981).
Description Qf Antiepileptic Drugs (AED)
The commonly used AED are summarized by Rail and Schleifer (1980).
Several of the barbituates,
currently

used

as AED.

long used as sedative-hypnotic drugs,
It

is thought

that while the

are

sedative

properties of phenobarbital are a result of generalized stimulation of
receptors for the inhibitory neurotransmitter gamma aminobutyric
its

acid,

anticonvulsant properties are more related to its potentiation of

inhibitory

pathways

that

are

recruited

during

discharge

of

epileptogenic foci.
Oral

absorption

It

of phenobarbital is slow but complete.

is

about 50% bound to plasma proteins and is evenly distributed over the
body.

Its major metabolite, parahydroxyphenobarbital, is inactive and

excreted in urine.
tonic-clonic

Phenobarbital is used for controlling generalized

and cortical seizures.

Other barbituates in use as

AED

are mephobarbital and metharbital.
Phenytoin is a widely· used and relatively well studied AED.
the

5,5-diphenyl non-sedative derivative of phenobarbital.

It is

Phenytoin

9

reduces
the

the development of maximal seizure activity and the spread of

seizure process from an active focus

nervous

system depression.

excitability toward normal,

without

Phenytoin restores abnormally

increa sed

modifies the pattern of maximal

electro-

shock seizures and reduces the duration of neuronal
Phenytoin affects the movement of ions
decreases

action

potential.

afterdischarge.

across cell

resting Na+ fluxes and the Na+ current,

influx depolarization,

causing central

membranes;

it

decreases the Ca+

and delays the K+ outward current during an

This leads to an increased refractory period and a

decrease in repetitive f i ring.
Phenytoin i s a weak acid (pKa 8.3) with limited aqueous so lubility
and dose-dependent elimination.
proteins and
metabolite,

It is extens ivel y bound

is widely distributed to

all

to

plasma

It's maj or

tissues.

the parahydroxyphenyl derivative, is inactive and excreted

in bile and urine.
Phenytoin

is effective

in controlling most forms

of epilepsy

except absence seizures and is also used in the treatment of
and cardiac arrhythmias.

psyc hos i s

Other hydantoins used to control seizures are

mephenytoin and ethotoin.
Primidone,

a deoxybarbituate,

is a cogener of phenobarbital.

resembles

phenobarbital

se lective

in modifying electroshock seizure patterns.

metabo l ized

It

in its anticonvulsant properties but is more

into two active products:

Primidone

is

phenobarbital and phenylethyl-

malonamide, and is effective in all but absence seizures.
Carbamazepine, an iminostilbene, is related to the tricyclic antidepressant drugs .

Its .anticonvulsant effects are simi liar to phenyto in

but its mechanism is unknown.

Carbamazepine is rapidly absorbed after

oral

10
administration and is approximately 80% bound to plasma proteins.

Its 10,11-epoxide metabolite i s also active.

It is used for temporal

lobe epilepsy alone or in combination with

generalized tonic-clonic

seizures.
Ethosuximide,
absence

a succinimide,

seizures.

is used primarily for

Both ethosuximide and

controlling

trimethadione

(to

be

discussed) offer protection against the convulsant action of pentyleneEthosuximide elevates the threshold for electroshock

tetrazol.

sei-

zures and blocks spiking activity in primary and secondary foci and the
associated clonic seizure activity produced experimentally in the rat.
Ethosuximide
inactivated

by

is

evenly distributed

hepatic microsomal
Other

metabolites.

succinimides

to

enzymes
in

all
into

use

tissues

and

is

inactive

several

are methsuximide

and

phensuximide.
Valproic

acid

is a simple branched-chain carboxylic

acid

used

against

a variety of seizures with minimum sedative and other central

nervous

system effects.

thought to

be

metabolism

The mechanism of action of valproic acid

an interaction with gamma-amino

and/or

augmentation

of

butryic

GABA-mediated

acid

is

(GABA)

postsynaptic

inhibition.
Valproate
administration,

is

rapidly and almost completely absorbed

is approximately 87% bound to plasma proteins,

equilibrated mainly in the extracellular space.
several

after oral
and is

It is metabolized to

products and may inhibit hepatic enzymes as indicated by

its

interaction with phenobarbital.
The oxazolidineone drugs are also used as AED.

Paramethadione and

trimethadione are used for controlling absence seizures.

Dimethadione,

11
the N-demethyl metabolite of tr imethadione, is also active.
Diazepam,

a benzodiazepine sedative-antianxiety drug, is valuable

in the management of status epilepticus.

Diazepam

suppresses

seizure activity produced by epileptogenic foci

spread of
cortex,

thalamus,

synaptic

systems.

products

by

the

in the

and limbic structures and facilitates GABA-mediated
It

reduction

is extensively metabolized to
of the ?-nitro group

to

an

a variety of
inactive amino

derivative , and to an active N-demethyl derivative.
Other AED less commonly in use are phenacemide (phenylacetylurea),
a straight chain analog of phenytoin; phenacemide, and acetazolamine, a
carbonic anhydrase inhibitor.
Chronic Toxicities Associated
with Antieoileotic Drugs
A review of many of the chronic toxicities resulting from the use
of AED is available (Oxley et a!, 1983).

The disorders encountered are

in the general categories of hepatic, hematological, connective tissue,
copper and ceruloplasmin,

calcium and bone,

motor and cerebellar, and

immunological.
Heoatic

disorders.

Severe hepatic damage is rarely encountered with

any of the AED currently in use.
toxicity
and

However,

numerous cases of

have been reported especially with phenytoin,

phenobarbital.

Only a few cases of· hepatic

therapy with .pa trimethiadone,

methoin,

hepatic

valproic

acid

damage following

and the benzodiazepines have

been reported (Jeavons, 1983).
Drugs may cause hepatic damage by several mechanisms.

Hepatotoxic

drugs cause direct damage to the liver; the effects are predictable and

dose-dependent.

In contrast,
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unpredictable, dose-independent effects

result from hypersensitivity or host idiosyncratic reactions,
metabolic

abnormalities .

Metabolic

abberations may have a genetic

or be the result of exposure to other agents

basis

alteration of drug metabolizing pathways (Zimmerman,
sitivity

and

such as

which

1978).

idiosyncracy can cause either necrosis

cause

Hypersen-

or cholestasis.

Hypersensitivity responses, frequently associated with rash, fever, and
eosinophilia,

generally appear from

1-5 weeks after

i s a prompt response to

initiation of

treatment

and there

contrast,

a toxic response from a metabolite may become evident from

a challenge dose.

In

one week to 12 months after initiation of therapy.
In most cases where AED are the cause of liver damage,

evidence

points to hypersensitivity or drug idiosyncracy as the etiology.
the possibility of hepatic disorders due to AED,

Given

it is advisable that

patients as well as clinicians be informed of possible side effects and
that the

patients be seen frequently,

months of therapy.

Warning signs for

especially during the first
phenytoin,

carbamazepine toxicities include skin rashes,
and

jaundice.

vomiting,
It

has

lymphadenopathy,
anorexia,

recurrence of seizures after initial control and

jaundice.

closely guard
thought

fever,

and

include malaise,

been

Those for valproic acid

phenobarbital,

6

recommended that a monitoring scheme be set up to more
against liver damage (Loyning et a!,

that multiple drug therapy

hepatotoxicity (Jeavons, 1983).

plays

an

1983).

important

It

is

role

in

Copper and ceruloplasmin levels.
have

been

found

to

Phenytoin monotherapy
cerulop l asmin
decreased both .
found

to

13
Various anticonvulsant medications

alter plasma copper and
has

been found to

ceruloplasmin

levels.

increase copper but

concentrations while valproic

ac i d and

ethosuximide

Primidone or carbamazepine monotherapy have not

alter either copper or ceruloplasmin levels.

not

In

been
recent

study, untreated epileptic children did not have significant changes in
either copper or ceruloplasmin concent rations as compared with normal,
age-matched control subjects (Fichsel eta!, 1983).
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Hematological disorders.
with marrow

Several of the AED drugs have been associated

suppression (Reynolds,

1983a).

In a number of

carbamazepine was the probable cause of aplastic
1975).

anemia

cases,

(Pisciotta,

Phenytoin may cause aplastic anemia especially when given

combination

with other drugs (Best,

associated with leucopenia,

1963).

Phenytoin has also

been

agranulocytosis, and thrombocytopenia.

one case of erythroid aplasia,
synthesis in erythroid cells,

phenytoin appeared to

specifically,

in

inhibited

In
DNA

the step of deoxyribotide

formation (Reynolds, 1983a).
Valproic

acid

thrombocytopeni.a,

has
and

been assoc iated
bleeding.

with

platelet dysfunction,

Suggested mechanisms

have

been

postulated (Reynolds, 1983a).
Several

cases of neonatal coagu lation defects have been

reported

in infants born to mothers treated with phenobarbital and/or phenytoin.
The

bleeding,

due to a depression of vitamin K-dependent coagulation

factors (II, VII, IX, and X) is correctable or preventable with vitamin
K therapy.

Phenytoin

has

also

been

shown

to

have this

effect

experimentally (Reynolds, 1983a).
Severa l of the AED have been associated with megaloblastic anemia
due to folate deficiency,
cell

(RBC)

abnormal.

folate

reflected by subnorma l serum and red

level s.

Serum vitamin 812

levels may

blood

also

be

Both folate and vitamin 812 (cobalamine) are necessary for

the maturation of the RBC (Guyton, 1981).

Macrocystis has been seen in

a large percentage of patients on combined

phenytoin and

primidone

therapy (Chanarin eta!, 1976).
In non -anemic patients, folate and vitamin 812 levels may still be
subnormal.

Low folate levels have been found in serum,

most commonly
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in patients
cells,

receiving multiple AED therapy,

and cerebrospinal fluid (Reynolds,

that phenytoin,
acid

phenobarbital,

and also in

1983a).

red

blood

There is evidence

primidone, carbamazepine, and valproic

exert some effect on folate metabolism but possibly by different

mechanisms.
induction
valproic

Several hypothesis have been postulated, including enzyme
by phenytoin,

acid

is not an enzyme inducer.

interaction

competitive
malabsorption

phenobarbital

between

of folic acid,

folate

and

carbamazepine;

however

The other hypotheses
coenzymes

and the

are:
drugs,

and increased demand for folic acid as a

coenzyme for AED-hydroxylation or for other enzymes

induced

by the

shown

several

drugs (Reynolds, 1983a).
Children

treated

hematological disorders:
hypofibrinogenemia.

with

valproic

acid

have

thrombocytopenia, prolonged bleeding time and

A dose

relationship to the drug

and

possible

relationship to its hepatotoxic effects have been suggested (Roche! and
Ehrenthal, 1983).
A deoxyuridine
folate deficiency

suppression

test has been developed to

in patients on long-term AED therapy.

assess

This

test

measures the ability of bone marrow cells to convert deoxyuridine to
thymidine for

DNA synthesis,

megaloblastic anemia.
study

has

a reaction specifically disordered

in

Although results have been conflicting, a recent

shown that the test is clinically

useful

in

detecting

significant folate deficiency (Burman, 1983) and concluded that megaloblastic anemia in patients on long-term AED therapy is due to folate
deficiency.
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Connective tissue disorders.
have been

A variety of connective tissue disorders

seen in patients receiving AED.

Gingival

hyperplasia,

a

proliferation of the gums and sometimes other tissues, is thought to be
caused from stimulation of fibroblasts due to folate deficiency.
occurs

in about one out of three epileptic

therapy.

patients on

The severity of this condition varies

levels of phenytoin

in

the serum and

aggravates this condition.

It

phenytoin

proportionally with

saliva.

Poor oral

hygiene

Other unknown factors are thought to be

involved in the etiology of gingival hyperplasia, such as the epileptic
condition itself, and age

(Schmidt, 1983a).

Facial changes occur in about two thirds of all institutionalized,
severe epileptic

The coarsened features

patients.

seen

thickening of the lips and subcutaneous facial tissues,
club- shaped

nose such that the

appearance.

Most often,

this

face

developes

condition occurs in

an

include

and a wide,
acromegalic

patients given

multiple drug therapy; however this condition has not been well studied
(Schmidt, 1983a).
Dupuytren's contracture,

a proliferation of elastic fibers

thickening of the palmer collagen fiber bundles,

and

is found in one third

of all male and one fourth of all female epileptic patients.

Ledder-

house syndrome, fibromas of the mucous membrane of the mouth and of the
plantar fascia of the foot, may then develop in these patients.
barbital
(Schmidt,

and primidone treatment have been linked to these
1983a).

Pheno-

syndromes

In a recent study (Schmidt eta!, 1983c) 4 patients

on phenobarbital therapy for either epilepsy (3) or migraine headaches
developed

Dupuytren's

contracture

and

Ledderhouse

Discontinuance of phenobarbital in the non-epileptic patient

syndrome.
resulted
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in

a regression of this condition .

Froscher and Hoffman (1983)

shown

that discontinuance of phenobarbita l in the majority of

with

Dupuytren's contracture

condition.

results

in

have
cases

an improvement of

the

A number of other factors are thought to be involved i n the

etiology of the above disorders including chronic trauma,

and duration

and dose of AED treatment.
shou lder syndrome,

A frozen
shou lders

stiffness

in

the

and other joints may develop in patients on phenobarbital or

primidone therapy.
this

a non-rheumat ic

condition .

Other connective tissue disorders may

This syndrome may be

reversed with physical

accompany
therapy

without drug discontinuance (Schmidt, 1983a, Janz and Piltz, 1983).
In

contrast to the above disorders,

AED have been shown to be

beneficial for wound repair and the healing of ulcers (Schmidt, 1983a).
In

a recent

study of children on AED therapy (Trimble and Corbett,

1983) hirsuties, gum hypertrop hy and low weights were noted.
levels

of serum phenytoin were associated with gum

hypertropy while

high levels of phenobarbital were associated with low relative
Hirsuties

and

High mea n

height.

height and weight abnormalities were associated with

i ncrea sed frequency of seizures but not with gum hypertrophy.
Lyell ' s syndrome,

a toxic epidermal necrosis,

number of patients receiving AED.
a drug with a 22% mortality rate,
related

has occured in

This is a severe ativerse reaction to
and any re-exposure to a drug or

drug to a patient that has shown a hypersen sitivity to

particular drug
carbamazepine,

is dangerous.
mep henytoin,

(Schmidt, 1983a).

a

This syndrome has

phenytoin,

been found

phenobarbital,

a

with

and primidone

Disorders Qf mineral metabolism.

attributed to AED therapy with vitamin D deficiency being
feature.
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been

Osteomalacia and rickets have

a common

Long-term and high dosage (usually multiple) drug therapy are

thought to contribute to these disorders.
hypocalcemia

and

An increased frequency

raised alkaline phosphatase levels have been

Under controlled conditions,

AED have been found to

of

found.

induce a mild

biochemically detectable vitamin D deficiency in spite of criticisms
that various factors,

namely outdoor activities and nutrition,

affect

serum 25-hydroxyvitamin D levels (Offerman, 1983).
The ability of several of the AED to

induce microsomal

mixed-

function oxidase activity and to stimulate biliary excretion is thought
to

be responsible for the development of vitamin D deficiency:

twenty

five-hydroxylation of vitamin D and various steroids is metabolized
mixed function oxidase enzymes.
is still active,
It

by

Although twenty five-hydroxy vitamin D

it could be further oxidized to inactive metabolites.

is known that vitamin D and its metabolites are biotransformed and

excreted

in

Enterohepatic

bile as acid,

neutral,

glucuronide or sulfate forms.

recirculation has been demonstrated to be important for

at least the 1,25-dihydroxy active metabolite (Offerman,
factors

1983).

These

are thought to play a role in the development of vitamin

D

deficiency.
Christiansen and

Tjellesen (1983) have presented evidence that

drug-induced

osteomalacia

osteomalacia.

Vitamin 02 but not 03 is effective as a treatment. There

is

is somewhat

unlike that of

evidence for drug-induced liver enzyme induction as

vitamin D deficiency,
involved.

classical

a cause of

however, other mechanisms are also thought to be

In
therapy
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a recent study of institutionalized epileptic patients on AED
(Berry et a!,

calc ium and

1983) serum twenty five-hydroxy

alkaline phosphatase levels were evaluated.

vitam in

D,

The authors

concluded that drug-induced hypocalcemia was exacerbated but not caused
by vitamin

D deficiency,

which

in turn

insufficient exposure to sunlight.

is

primarily

induced

Vitamin D therapy does

by

correct

levels toward normal but does not correct the concommitant hypocalcemia
indicating that these two deficiencies are not para llel.
group of epileptic patients (Krause eta!,
that disturbance

In

1983) there was

another
evidence

in bone metabolism is a problem after initiation of

AED treatment, particularly in children, followed by a normalization of
metabolism.

Long-term therapy (over 10 years) may again be a sensitive

period of drug-induced bone metabolism imbalance.
carbama zep ine monotherapy had

hypocalcemia,

elevated alkaline phosphatase levels,

Several patients on
hypophosphataemia

suggesting

and

that carbamazepine

alone may disturb bone mineral metabolism (Keranen et a!, 1983).
A recent survey of institutiona l ized epileptic patients indicated
t hat the type of seizure may be more related to the number of sustained
fractures incurred rather than drug treatment; namely tonic se izures in
which the patients fall rigidly to the ground increase fracture

risk

(Allen and Oxley, 1983).
~

anQ cerebellar function alterations.

Cerebellar dysfunction

(reversible and permanent) has occurred with phenobarbital,
and phenytoin therapy.

primidone

However, Dam (1983) has shown that in patients

with a low density of Purkinje cel l s, there is a greater correlation of
degeneration

of

Purkinje cells to

severe

epilepsy

(frequent
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Phenytoin does not induce

convulsions) than with high phenytoin dose.
neuropathological

lesions

resistant versus

seizure

in experimental animals.

A comparison of

seizure sensitive Mongolian gerbils

has

demonstrated that neuropathological lesions in the cerebellum were
found

only

caused

in the sensitive strain;

by basic

the lesions were assumed to

biochemical derangements associated with

be

epileptic

hyperactivity (Dam, 1983).
Phenytoin and to a les ser extent other extent AED can
dyskinesias,

an

impairement of

cause

the power of voluntary movement

resulting

in fragmentary or incomlete movements.

cerebral

damage may

facilitate

Coexisting organic

the development of

drug-induced

dyskinesias.

Increases in dose of one drug or addition of another may

trigger this

impairment.
may

dyskinesias

be

The mechanism by which

related

to

its

ability

phenytoin causes
to

alter

brain

neurotransmitter systems (Dravet eta!, 1983) .
MutaQenjc and teratogenic

~

Valproic acid and phenytoin have

been found to be teratogenic in an in vitro culture assay in
dependent manner.

The abnormalities

produced in organ culture of

embryonic mice included open neural tubes,
craniofacial deformities.

and

results

abnormal body curvature and

Growth and development were also retarded in

these embryos (Bruckner eta!,
rats

a dose-

1983).

Valproic acid is teratogenic in

in .pa resorptions and a number of skeletal

and

visceral malformations (Ong eta!, 1983).
Valproic

acid

appears ·to be readily

transported

across

the

placenta and achieves higher serum concentrations (1.4x) in the

infant

than

longer

the mother with

a bi ological

half-life three times
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(Dickinson et
valproic

a!,

1979).

Epidemiological studies have

shown that

acid may cause neonatal transformations such as spina

aperta in humans (Robert et a I, 1983).

bifida

Various studies have shown that

mothers on AED have a 6% rate of malformed children as compared to 2.5%
in control mothers.
Chromosomal

damage in leukocytes has been found in patients on

long-term carbamazepine or phenytoin monotherapy.

Both chromosomal and

chromatid exchange-type aberrations were seen (Herna and Obe, 1977).
Overview Qf the Immune System
The

immune system consists of an

lymphoid organs and tissues.
thymus

and

spleen,

In mammals,

the central tissues are the

bone marrow and peripheral tissues are the

tonsils,

these tissues
they

interconnecting network of

and

Peyer's patches.

lymph

nodes,

Lymphocytes are produced

and move among these tissues in blood and

in

lymph where

interact with antigens and with each other while in the

system

(Kimball, 1983).
An

immune

response

is

defined as a "altered

specific configuration that develops
(Kimball,

1983,

pp.3).

specificity and memory.

following

response.

responses:

humoral

contact with

The response must meet

it"

the criteria of

An antigen is a substance that when introduced

into an animal with a functioning immune system,
immune

reactivity to a

can elicit a specific

Two main effector mechanisms mediate
immunity

(antibody mediated)

immune

and cell-mediated

immunity.
In
{T-cells)

the cell-mediated branch of the immune

system,

T-lymphocytes

of different types and specificities are the main

effector
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Antigenic stimulation ofT-cell s results in cell proliferation

cells.

(division)

and differentiation of T-ee!! populations

specific antigenic

determinants on the antigen.

which
Clones

recognize
(identical

progeny) of these lymphoblast cel ls are responsible for such actions as
delayed-type hypersensitivity (T

), cytotoxic activity (T ) directed
DTH
c
against graft cells or infected cells, helper activity (T ) which aids
H
in T killing and antibody production, and suppressor activity (T )
which

c

prevents overaction of the immune system such as fo un d in

s

auto-

immune disorders.
In the humoral branch of the immune system,

antigenic stimulation

of B-lymphocytes {B-cell s) results in proliferation and differentiation
of those ce lls which recognize antigenic determi nants on the antigen.
These

lymphoblasts differentiate into plasma cells which

produce and

release antibody of the same specificity as the

stimulated B-cells;

i.e., they are specific for the eliciting antigen.

Antibodies than act

as intermediaries in a series of reactions , including the activation of
the complement cascade for lysis,

to help rid the body of the foreign

antigen.
Natural

killer

(NK)

cells are a subpopulation of

lymphocytes

responsible for the recognition and killing of tumor ce ll s which

arise

spontaneously or via chemical or physical agents in the body.

These

cells are not truly immune cells because they require no prior exposure
(sensitization) for effective ki lling and ha ve no memory function as do
other

lymphocytes.

They are thought to be important for surve illance

and destruction of neoplastic ce lls in vivo.
for

Lymphocytes

antibody-dependent cell-mediated cytotoxicity (ADCC)

responsible
kill

cells
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coated with antibody specific to these target cells.

These lymphocytes

are possibly identical to the NK cells.
Blood monocytes and their tissue counterparts,
are accessory cells of the immune system.
responsible for the

They are phagocytic and

ingestion and breakdown of foreign

matter including live cells.
in their tasks

the macrophages,

Macrophages assist T- and

particulate
B-lymphocytes

by the processing and presentation of antigen to T
H

cells.
The various

cells of the immune system are derived

marrow precursor cells.
whithin

the thymus.

T-cells mature while in temporary

from

bone

residence

Normal immune responses require recognition

and

cooperation of different cell types and coordination with a variety of
factors.

It

is through this

complex interplay that the

protected from foreign agents and self · destruction.

body

is
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li.f.ed.s Qf Anti ep i Iept i c
Ib..e_ Immune ~

Several

~ _Qfi_

of the widely used AED have been shown to

modulating effects

in

some patients.

Many

have

patients on

phenytoin therapy have developed low secretory and

immunolong-term

serum lgA

levels

(Chiu et al, 1982; Gilhus and Aarli, 1981a; Martinez-Cairo eta!, 1980;
Fossan and Aarli,

1979;

Aarli, 1976a, 1976b).

Decreases i n secretory

lgA can resu lt in an increase in frequency of
(Gilhus and Aarli,

1981a;

respiratory

Aarli and Fontana,

infections

1980) and there is an

increased tendency for phenytoin-treated patients to develop recurrent
respiratory infections (Aarli and Gilhus,
have also found

in duodenal fluid of

(Martinez-Cairo eta!, 1980).
appears

to

1983).

Decreased IgA levels

patients

receiving

phenytoin

Predisposition to develop lgA deficiency

be genetically determined

(Aar li

and

Gilhus,

1983).

Anderson and Moseklide (1977) have shown decreases in serum lgA in some
patients

but

increases

in others.

Serum !gA deficiencies can be

reversed by withdrawal of phenytoin therapy (Aarli,

1976a).

deficiency may be associated with in creased serum lgM and

Serum !gA
!gO

levels

(Pereira et a I , 1983 ).
The
following
1981;

phenytoin therapy.

Suppression of !gG (Czlonkowska et a!,

Anderson and Moseklide,

subclasses
1981;

levels of other serum immunoglobul ins have also been altered

(Fontana et a!,

1977;

1978c),

Anderson and Moseklide,

Aarli,

1976a), imbalance of IgG

elevation of lgM' (Anderson et a!,

1977), depression of IgM (Aarli, 1976b)

and increases in !gE and !gO (Blanco eta!,

1977 ) have been reported.

Many of these changes were slight such that the overall effects on the
patients were

likely to be

insignificant.

An

alteration of the
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compositio n or quality of the cerebrosp inal fluid IgG has also been
found in phenytoin-treated patients (Fossan and Aarli,

1979) and

reduction of cerebrospinal fluid lgG concentrations has been observed
(Fossan, 1976).

Deposits of immunoglobulins in the skin have been

found (Meistrup-Larsen et al, 1979).

A severe panhypogammaglobulinemia

has been found in a few patients (Pereira et al, 1983).

It has been

suggested that B-cell differentiation is altered by phenytoin (Seager
et al, 1975).

In particular, there may be several blocks of the normal

progression in B-cell differentiation in a manner similar to that found
with adult-onset hypogammaglobulinemia.

These blocks could lead to the

increase in IgD found in some of the IgA-deficient patients (Pereira et
al, 1983).
A decrease in numbers of T-cells has been found in epileptic and
non-epileptic patients receiving phenytoin (Martinez-Cairo et al,
1980).

The mean percentages ofT-cells and monocytes were decreased in

patients on phenytoin therapy (Chiu et al, 1982).

Evidence ofT-cell

dysfunction has also been observed (S hakir et al, 1973)

and decrease

in total lymphocyte numbers have been noted (Gilhus et al, 1982 ba nd
1982c).
Supression of in vitro lymphocyte blastogenesis with phytohemagglutinin and pokeweed mitogen by serum factors has been found in
patients with brain tumors treated with phenytoin (Neuwelt et al,
1983).

In epileptic patients receiving phenytoin, phytohemaggl uti ni n

blastogenesis was slightly depressed (Gilhus et al, 1982 b; Czlonkowska
et al, 1981; Yabuki and Nakaya, 1976).

Phenytoin added directly to

lymphocyte cultures from patients depresses lymphocyte response but a
comparison of these patients after initiation of drug therapy versus
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pre-drug responses showed a tren d to increased responsiveness to
pokeweed mitogen, concanavalin A and suboptimal levels of phytohemagglutinin in those with low serum IgA (Gabournel et al, 1982).
A number of patients on long-term hydantoin treatment, including
phenytoin, have developed lymphoma (malignant or Hodgkin's).
possible correlations

There are

between the immunosuppressive action of

hydantoin derivatives and tumor induction (Jungi et al, 1975).
The percentages of l ymphocytes forming rosettes with sheep red
blood cells was decreased in epileptic patients receiving no drug
J

therapy (Czlonkowska and Korlak, 1980) and with patients on AED therapy
(Fontana et al, 1978c); however eleva ted responses (Czl onkowska et al,
1981) and normal responses have also been observed (Gilhus et al,
1982c).
Patients on phenytoin therapy have been found to have reduced
concentrations of complement components C1-inhibitor and C4 (Aarli and
Gil hus, 1983).
Several changes in normal immune function have been reported
following carbamazepine therapy.

An increase in serum IgA and IgG were

found in one study where the increase was positively correlated to
increasing carbamazepine concentraions and inversely correlated with
age (Strandjord et al, 1980).
serum lgG and

Igr~

In another study, a trend for increased

levels was noted as well as a significant fall in

phytohemagglutinin-induced blastogenesis (Czlonkowska et al, 1981).

A

marked decrease in serum IgA and lgM levels occured in some patients
during the first month of carbamazepine therapy (Gilhus et al, 1982a ).
However other studies have failed to confirm immunomodulating effects
of carbamazepine: Gilhus et al (1980 ) found no significant difference
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in salivary IgA although a trend of elevated salivary IgA, IgG, and
levels was

found.

Gilhus

et al,

(1982d}

found

no

Igl~

significant

differences in nasal and serum IgA, IgG and IgM levels or in the number
of days with respiratory tract disease symptoms in epileptic patients
receiving carbamazepi ne therapy.
One patient

developed lupus erythematosus while receiving

carbamazepine therapy.
were low or absent.

Salivary, gastric juice, and serum IgA levels
No IgA-producing plasma cells were found o n the

rectal mucosa and bone marrow.

Numbers of surface IgA+ B-lymphocytes

were below normal, and there was a decreased capacity to develop both
circulating antibodies ·and delayed hypersensitivity against test
antigens (Takigawa et al, 1976}.
There is little indication that other AED have effects on the
immune system. Cells from patients with brain tumors treated with
phenobarbital have a decreased in vitro lymphocyte blastogenesic
response to mitogens via a suppressive factor in
1983} .

serum (Neuwelt al,

Blanco et al (1977} found seru m IgA deficiency in one out of 20

c hildren being treated with phenobarbital.
Patients on multiple drug

therapy

have

shown decreases in

production of specific antibody to such antigens as parainfluenza virus
III (Czlonkowska and Iwinska, 1977}.
The varying degrees of immunomodulation seen in patients on AED
indicates that there are likely other factors besides the AED that have
a rol e in suppression or stimulation of various components of the
immune system.

For example patients on phenytoin may have no change in

IgA levels (Modeer et al, 1981}, mild depression or severe depression
(Pereira et al, 1983}.

In one study, IgA suppression was found to be
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more related to the history of febrile convulsions than to the type of
epilepsy or drug therapy (Gilhus and Aarli, 1981b).

Epileptic patients

not receiving medication have shown no antibody changes in some studies
(Aarli, 1976b; Yabuki and Nakaya, 1976) whereas follow up studies on
patients on phenytoin therapy show a decrease _in serum IgA only after
start of treatment (Aarli, 1976b; Fontana et al, 1976).
epileptics have at times shown antibody imbalances
1978b; Haldorsen and Aarli, 1977).

Relatives of

(Fontana et al,

While some studies have shown that

phenytoin may depress in vitro blastogenesic response to phytohemagglutinin, other studies have shown that a greater than expected number of
patients have a low responsiveness to mitogens prior to treatment
I

(Gabourel et al, 1982), and in fact serum lgA-deficient epileptic
patients receiving phenytoin have shown increased lymphocytic responses
to mi togens.
Various authors have stated the importance of aquired or genetic
factors in determining whether a patient will suffer either suppression
or stimulation of immune responses while receiving AED (Chiu et al,
1982; Anderson et al, 1981; Blanco et al, 1977).

HL-A2 antigen is

associated with decreased IgG titers seen with phenytoin and carbamazepine therapy and with immunoglobulin subclass imbalance (Fontana et
al, 1978c).

HL-A7 antigen has a significantly increased frequency

among epileptic patients while HL-A12 antigen has a low frequency.
HLA-B7 is associated with Lennox-Gastaut epilepsy (Smeraldi et al,
1975). Tartara et al (1981) found the common feature of immunological
disorders more related to early onset of seizures and AED treatment
rather than the specific therapy or the clinical type of epilepsy.
Bo th epilepsy itself and AED have been associated with autoimmune
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phenomena.

It is possible that epilepsy itself may have an immuno-

logical basis in some cases.

Divalent and monovalent antibodies to GM

1 ganglioside injected into the sensori-motor cortex of the rat induces
recurrent epileptiform activity (Karpiak et al, 1982).

It has been

proposed that epileptic discharges could be the result of an autoimmune
response to either an antigen released during tissue destruction or an
infective agent; antibodies may block transmitter receptor sites at
synapses and reduce synapti c transmission (Ettlinger and Lowrie, 1976).
The types of auto-antibodies found in some epileptic patients
include antinuclear (Chiu et al, 1982; Anderson and Moseklide, 1977),
anti-RNA (Ooi et al, 1977) anti-mitochondrial (Anderson and

l~oseklide,

1977), and anti-muscle and anti-brain nicotinic acetylcholine receptor
(Fontana et al, 1978a).

Po~ova et al (1975) found a 31% incidence of

brain autoantigens and an 8% incidence of anti-brain antibodies in
epileptic patients receiving AED.

Lymphocytotoxins with activities

against T- and B-lymphocytes were found in 30% of patients on phenytoin
(Ooi et al, 1977).

It has been postulated that AED can activate a

latent autoimmune response and modify its natural course for the worst
(Alarcon-Segovia et al,

1972).

Ethosuximide (Tor et al, 1979), carbamazepine (Takigawa et al,
1976), and other AED are considered lupus erythematosus-activating
drugs (Alarcon-Segovia and Fishbein, 1975).

In several patients an

unquestionable correlation was found ·between the appearance of seizures
and the action of certain allergens.

However, allergy is only rarely

considered to be the cause of epileptic seizures (Dzi alek, 1975).
Pechadre et al (1977) have reported that out of 10 children with
severe epilepsy that were treated wi th repeated large doses of gamma
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globulin, 7 showed marked improvement in behavior and 8 showed a
disappearance in seizures with EEG improvement. Epilepsy may then be
triggered by a combination of an inadequate immune system and an
infectious agent.
Despite what is known concerning immune deficiencies associated
with epilepsy and AED, a unified concept of their relationships cannot
as yet be formulated (Cereghino, 1983).
A number of disorders , ranging from mild to severe may affect the
same individual receiving AED (Christe et al, 1983).

A number of

factors appear to predispose a patient to chronic toxicities: young
children may be more susceptible to the toxic effects of these drugs.
Long-term therapy increases the risk of chronic toxicities as does
mu 1tip 1e drug therapy .

There is evidence that mu 1tip l e drug therapy

has little advantage over single drug therapy in contro 11 i ng seizures
and may greatly increase toxicity risk.
diet,

pregnancy,

Institutionalization, poor

and the presence of concurrent illnesses and

disabilities increase toxi c ity risk.
retardation increase toxicity risk.

Brain damage and mental

Repeated acute toxicity can

increase risk by damaging peripheral nerves.

Reynolds (1983b) has

outlined the factors predisposing individuals to chronic toxicities and
has recommended that both physicians and patients be aware of the side
effects of AED and their signs. The importance of correct diagnosis
and therapy is stressed. Furthermore, early and effective treatment is
a safeguard to patients.
possible.

Lastly, therapy should be withdrawn when
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CHAPTER Ill
REDUCED NATURAL KILLER CELL ACTIVITY, NUMBERS OF
LEU11+ CELLS, AND OKT4+/0KT8+

RATIO

IN EPILEPTIC PATIENTS.
Introduction
The

drugs effective

in controlling

seizures

are

variously

associated with a number of chronic toxicities including toxicity to
the immune system
are

(Oxley eta!, 1983) . Included among these toxicities

depression of serum and secretory IgA titers seen in patients on

long-term phenytoin treatment (Yabuki and Nakaya,

1976; Martinez-Cairo

eta!, 1980) and decreases in specific ant ibody titer found in patients
on multiple antiepileptic drug (AED) therapy (Sorrel

et a!,

1971;

Czlonkowska and Iwinska, 1977).
A limited number of studies have been conducted on lymphocytic
function of patients on long-term AED therapy.

A decrease in mitogenic

response to phytohemagglutinin (PHA) and pokeweed mitogen

(PWM)

has

been found in association with phenytoi n and phenobarbital treatment of
patients with brain tumors (Neuwelt eta !,
a!.

(1978)

1983).

Further, Shakir et

fo und evidence of suppressed T-ee!! function

receiving phenytoin.

However ,

it has

in

patients

been suggested that

immune

alterations found in epileptic patients are not necessarily a result of
AED since abnormalities

have been fou nd in

medication (Gabournel eta!,
relative

roles that AED,

1982).

patients not

receiving

Limited data are available on the

disease processes of epilepsy,

and genetic

f actors play in immune abnormalities seen in epileptic patients.
The

present study assessed

natural

killer and

killer

cell

activities
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of peripheral blood mononuclear cells (PBMC) isolated from

children and

adult epileptic patients.

Healthy siblings were

studied as a means to assess a genetic role in immune
responses
PWM

to the lymphocyte mitogens concanavalin A (con A),

were

also

subpopulations
7.2(Ia),

function.

and

investigated.

and
Leu

Enumeration of

the

subsets which expressed the markers
11

were made.

also
PBMC

PHA and
lymphocyte

OKT4,

OKT8,

Immunologic studies of epileptic

children were of particu l ar interest since few data are available from
you ng patients .
Materials Q.Q.Q. ~
Experimental subjects.
both epileptic

The human subjects used in thi-s study included

patients and age- and sex-matc hed healthy volunteers.

The epileptic children were affiliated with the Developmental
for

Handicapped Persons at Utah State University.

receiving

a variety of medications and differed

Center

The patients were
in

their treatment

regimens and medical histories. The ages of the children ranged from 416 years
included
patients,

{patients ) and from 3-18 years

(controls).

The sib l ings

5 children aged 6-14 years and 1 adult (age 25).

Four adult

ranging in age from 24-35 years, and up to 46 healthy adults

aged 20-45 were also studied.
Seoaration of PBMC.

PBMC were separated by centrifuging freshly

drawn blood on a Ficoll-Hypaque density gradient, rinsed, and suspended
in

RPMI-1640 medium

(Gibco,

Grand

Is land ,

New

York)

containing

penicillin (100 .pa units/ml), streptomycin (100 mcg/ml), and 10% fetal
bovine serum (Hyclone Laboratories, Logan, Utah).
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51
The details of the

Cr technique have

been described (Warren et a!, 1976). PBMC in concentrations of 5, 2.5,
6
51
1.2, and 0.6 X 10 cells / ml were incubated with
Cr-Jabelled K562
5
PBMC and target cells at
target cells suspended at 1 x 10 cells/mi.
0.1

ml

each were incubated together in triplicate

in

round

bottom

co . An a! iquot of
2
Beckman
gamma counter.
supernatant was
a
51
Results were expressed as a percent
Cr-release relative to

tissue culture plates for 4 h at 37C in
removed

5%

and counted in

spontaneous (target cells in medium alone) and maximal release

(target

cells in 0.25 % saponin):
Percent Release

experimental cpm - spontaneous cpm x 100
maximal cpm - spontaneous cpm

Lymphocyte enumeration.

PBMC were depleted of macrophages by allowing

adherent cells to attach to plastic culture dishes for 1 hr.
adherent

The non-

PBMC were enumerated with the rosette assay for total

T-

cells and the complement-mediated cytotoxicity assay for lymphocyte and
lymphocyte subpopulation proportions.
were

incubated

antibodies:

in Microtest

OKT4

for

II

For the latter assay, the cells
plates with

helper/ inducer

various

T-Jymphocytes,

monoclonal
OKT8

for

suppressor/cytotoxic T-lymphocytes, (Ortho Diagnostic Systems, Raritan,
New Jersey), 7.2 for the !a antigenic determinant on B-lymphocytes (New
England Nuclear,

Boston,

with Leu 11 for an

Massachusets), and on a few of the subjects,

NK cell subpopulation (Becton Dickinson Monoclonal

Antibody Center, Mountain View, California).
followed

by another

incubation

and the

determined by trypan blue exclusion.

Complement was then added
percent viable cells

was

Percent lysis was calculated as

lysed cells / total number of lymphocytes counted.
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Lymphocyte

The lymphocyte blastogenesis assay was

blastogenesi s .

carried out as previousl y described (Mickelson et al,
lymphocytic

responses to the mitogens PHA,

1981).

Briefly,

and PWM (Gibco) and con A

(Flow Laboratories, Mclean, Virginia) were assayed by culturing 1 x
5
10 PBMC with various concentrations of mitogens in flat bottom 96 well
tissue culture plates. After the cultures were incubated for 68 h in 5%
CO , tritiated-thymidine was added for an additional 4 h incubation.
2

The cells were harvested and tritiated thymidine incorporation counted
with a scinti ll at ion counter.
Antibodv-deoendent cell-mediated cytotox icity
assay was

(ADCC)

~

carried out in a fashion similar to that of the

except the targets were YAC-1 murine lymphoma ce lls.
concentrations of 10,

5,

2.5, and 1.2 x 10

6

This

NK assay

PBMC (0.05 ml) in

cells/ml and in 40% heat-

inactivated fetal bovine serum were incubated in round bottom wells
51
5
with 0.1 ml
Cr-labelled target cel l s suspended at 2 x 10 cells/ml
and

0.5 ml of rabbit anti-mouse thymocyte

Walkersville,

serum

(M.A.

Bioproducts,
51
Mary land) with a final dilution of 1/1000. Cr -release

was quantitated as in the NK assay.
Stat istical analysis.
means,

Data were analyzed with t-test for different

with analysis of variance,

or simple linear regression and the

95% confidence interval for a normal distribution.

Blastogenesis data

were analyzed after log transformations of the counts using

geometric

means and variances .

PBMC from epileptic patients,

healthy siblings, and
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unrelated healthy subjects were tested for natural killer cell activity
51
(Figure III-1). The mean percent Cr releases effected by PBMC of the
epileptic patients and their healthy siblings were significantly

lower

at each effector to target cell ratio than that of the healthy control
Although the siblings of the epileptic patients had induced

subjects.
somewhat

lower mean percent releases than the

releases

were not

epileptic

significant.

children were

patients,

these

lower

Mean releases effected by cells

similiar to those of the patients

shown

from
in

Figure III-1 and were significantly decreased from those of the healthy
children (p

<

. 01,

separate data not shown).

Al so,

3 of 4 adult

patients had lower activities than healthy adults.
Lymphocyte subset analysis.
used to

The monoclonal antibody anti- Leu 11 was

estimate the proportion of NK cells

bearing the

determinant in 13 of the patients and healthy subjects.
correlation was found

Leu

11

A significant

between the proportion of Leu 11+ cells and

NK cell activity (Figure III-2, r= 0.68 for the 50:1 effector to target
cell ratio). In addition, 6 epileptic patients included in this portion
study had a significantly lower proportion of

of the

Leu

11+ cells

(mean of 9.5% ± 5.0) than 6 unrelated healthy subjects (14.4 %z 3.9) .
The epileptic patients had a significant ly lower OKT4+/0KT8+ cell
ratio

as compared to that of healthy subjects (Table III-1).

siblings

also had

a lower ratio although

addition to data shown in Table III-1,
ratio

of 1.54 ±0.5 which was

not

Healthy

significantly.

In

epileptic chi ldren had a mean

significantly lower than that of healthy

children who had a mean ratio of 2.3 z0.9.

Adult patients had a lower
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FIGURE III-1. Natural killer cell activity expressed as mean percent
51
Cr release and standard error of the mean at various ratios of
effector to target cells.

Peripheral blood mononuclear cells

(PBMC)

were isolated from 46 healthy unrelated subjects including 10 children
and

36 adults IZZJ, 19 epileptic patients inc luding 15 children and 4

adults

1111 ,

adult ~ .

and 6 healthy siblings

including 5 children and

Mean releases effected by PBMC from patients and

their

siblings were significantly lower at each effector to target cell ratio
(p< 0.001).
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between

=

0.68, p< 0. 05) was found

percent Leu11+ peripheral blood mononuclear ce lls and

killer cell
patients

A significant correlation (r

e

activity of various
and

sibling •

effector to target cell ratio of 50 : 1.

su bjects:

6

healthy

natural

0

, 6

Cytotoxicity shown is from the
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TABLE III-1.
LYMPHOCYTE ENUMERATION OF EXPERIMENTAL SUBJECTS
Group

a
N

Healthy
Subjects

15

Patients

17

Siblings

6

OKT4+/ 0KT8

7.2+

c

d
RFC%

WBC

2. 14f
0. 75
g
1.54
0.42

13.4
5.5

77.4
7.8

7235
1911

15.9
7.5

77.9
8.3

7235
2261

1.68
0.37

14.6
4.7

79.4
2.7

6290
0831

b

e

a.

Numbers of subjects studied.

b.

Mean ratio of the proportion of peripheral blood mononuclear cells

which were OKT4+ to OKT8 +.
c. Mean percent of monocyte-depleted peripheral blood mononuclear cells
positive for the monoclonal antibody determinant 7.2.
d.

Mean

percent of

rosette forming cells

from

peripheral

blood

mononuclear cells depleted of macrophages.
e.

Total white blood cells as determined from aliquots of whole blood.
3

Values expressed as mean x 10 per mm
f. Standard deviation of the mean.
g. Significantly reduced (p

<

0.05).

3

ratio of
±0.4,
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1.9

1.7 ±0.4 compared with healthy adults with a ratio of

however this difference was not significant.
The monoclonal antibody anti-7.2 was used to estimate the numbers

of 8-cells in PBMC depleted of monocytes (Table Ill-1).
were found

in the percent of 7.2+ cells from

No differences

epileptic

compared with that found in cells from healthy

patients as

subjects.

A T-ee!!

rosetting assay with sheep red blood cells was done as an indication of
total T-cells and the percent rosette-forming cells (RFC) are listed in
Table

III-1.

Cells from neither children nor adult patients

deviations

from the normal range of 70-80 percent.

the total

white blood cell (WBC) counts for the

subjects.

These counts were quite

variable

showed

Also presented
various
and

groups

is
of

there were no

significant differences seen between the counts obtained from patients
and healthy subjects.
Lymphocyte

blastogenesis

assays.

Responses

to

concentrations of the T-ee!! mitogens PHA and Con A and

several
the

B-ee!!

mitogen PI<M are shown in Figures III-3, !11-4, and 111-5, respectively.
Considerable variation was observed in response to these mitogens
no

significant differences among PBMC from the

various

and

groups were

found.
Mitogenic

responses

of

PBMC from

5 epileptic children who

displayed symptoms of autism were analyzed separately and were found to
be significantly decreased for PHA,

Con A,

and PWM.

Details of these

studies will be presented and discussed elsewhere (Warren eta!, 1985).
In contrast to findings with the NK cell assay,
activity by cells of

epileptic patients was

not

ADCC

significantly
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thymidine

Mean

and

incorporat ion of count s per minute of

standard error of

mononuclear cells from

the mean

17 unrelated healthy

by

tritiated

peripheral

subjects

blood

including 9

children and 8 adults t22LJ, 13 epileptic patients including 9 children
and

4 adults

adult~'

1111,

following

phytohemaggutinin.
results
su bjects.

and 5 healthy siblings

obtained

No

incubation with

including 4 children and 1
vario us

significant differences

using cells from epileptic

concentrations of
were found

patients

and

between
healthy
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thymidine

Mean

and

incorporati on of counts per minute of tritiated

standard error of the mean

mononuclear celts from

17 unrelated

children and 8 adults~,
and

4 adults

adult~.

concanava lin

1111 ,

peripheral

subjects

blood

including 9

13 epileptic patients including 9 ch ildren

and 5 healthy siblings including 4 children and

following
A.

healthy

by

incubation with

various

concentrations of

No significant differences were found between results

obtained using ce lls from epileptic patients and healthy subjects.

42
10

9

8
7
0
0

S2
X

5

~

a..
u

-4

3

2

0.06

FIGURE

111-5.

thymidine

Mean

and

incorporation of count s per minute of

standard error of the mean

mononuclear cells from

16 unrelated

children and 9 adultsi'2Zl,
and 4 ad ult s adult ~,

.

subjects.

obta ined

by

healthy

blood

including

7

13 epileptic patients including 9 ch il dren

and 5 healthy siblings

No

tritiated

peripheral

subjects

incl uding 4 children and

follow ing incubation with various

po keweed mitogen.
resu lts

0.015

0.03
PWM,%

sig ni ficant differences

usi ng cel ls from epileptic

concentrations of
were found

patients

and

between
healthy
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different from that induced by PBMC of the siblings of the patients or
the other healthy subjects (Figure 111-6).
Discussion
The current study presents evidence for altered immune function
and

lymphocyte subsets of epileptic

Specifically,

patients and their siblings.

NK cell activity was found to be significantly depressed

in epileptic patients and their s iblings .
of

In addition,

the proportion

Leu 11+ NK cells was significantly lower in epileptic patients than

in healthy subjects.
and

A correlat ion was found between NK cel l activity

percent Leu 11+ cells,

observed
cells

in

suggesting that the low NK cell

activity

some of the patients may be due to a low proportion of

in the

blood

bearing

this

determinant.

However,

other

mechanisms, such as impaired lytic activity, could be operating.
Evidence indicates that NK cells play a vital role in host defense
against
1984).

virally

infected and transformed

The reduced

(tumor)

cells

(Herberman,

NK cell activity found in the patients and

their

siblings may not be of a level considered to be clinically meaningful,
and

in

fact

none of the experimental subjects in

considered to be immunologically compromised .
cell

activity could

be

responsible for

However,
the

susceptibility to respiratory infections seen in
treated

with

phenytoin

(Gilhus and Aarli,

this

study were

a depressed NK

slightly
epileptic

1981a).

increased
patients

Since only 6

sibli ngs were availab le for study, the association of a reduced NK cell
activity in these subjects must be regarded as tentative.
NK cells produce and are activated by various lymphokines and

are

involved in immune regulation and activation (Herberman, 1984; Scala et
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FIGURE III-6.

Antibody-dependent ce l l-mediated cytotoxicity expressed

as mean percent

51

Cr release and standard error of the mean at various

ratios of effector to target cells.

Peripheral blood mononuclear ce ll s

were isolated from 9 unrelated

he~lthy

adults ~ '

patients

adults •
adult

13

• and

rn.

No

epileptic
5

healthy

subjects including 1 child and 8
including 9 children and 4

sib! ings

including

significant differences were found

4 children and
between

results

obtained usi ng cells from epileptic patients and hea lthy subjects.

a! ,

1984).

influence

Thus,
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low numbers or reduced activity of NK ce ll s could

immune functions

other than NK ce ll activity or may

be a

reflection of other immune abnormalit ies .
A significantly

lower ratio of OKT4+/0KT8+ cells

was

found

in

epileptic patients. Altered ratios sometimes are associated with immune
deficiency if the ratio is low,

such as that seen in

deficiency syndrome (Fauci eta!,

1984) or autoimmune mediated disease

such as mult iple sclerosis (Bach eta!,
the ratio i s high.

acquired immuno-

1980; Reinherz eta!, 1980) if

Epileptic patients on multi-drug therapy have shown

lower specific antibody titers for parainfluenza virus III (Czlonkowska
and

Iwinska,

1977)

and

some

patients on

phenytoin therapy

delayed-type hypersensitivity to common test antigens (mumps,
and

lack

Candida,

Streptococca l antigen) and fail to produce antibody to Sa lmonella

typhi antigen (Sorrel et al, 1971).
In

contrast to observed differences in

deviations

in ADCC

activity were found

from

NK cell
cells

killing,

no

isolated from

patients versus healthy subjects. Evidence is accumulating that ADCC is
likely

mediated by a different mechanism than NK cell killing

and Williams,

(Koren

1978; Suthanthiran eta!, 1984). Blastogenic response to

T-ee!! and B-ee!! mitogens were found to be variable and no significant
differences were seen except in

epileptic patients who also expressed

the

symptoms of autism

(discussed separately in Warren eta!,

The

percent of monocyte-depleted PBMC forming rosettes with

1985).

SRBC

(an

indication of total T-cells in this population) from the patients were
within the normal range.

This finding contrasts with previous studies

demonstrating decreased

RFC in epileptic patients not

(Czlonkowska and Korlak,

1980) and patients receiving AED (Fontana et

receiving AED
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a!,

1978c)

but agrees with

the report of Gilhus eta!.

(1982b) who

found normal proportions of RFC in epileptic patients treated with AED.
The varying degrees
patients on

AED therapy

of

immune

alteration

indicate that factors

seen

in epileptic

other than

those

associated with AED likely play a role in modulating various components
of the immune system in these patients.
probably a genetic mechanism.
in

association with

Chief among these factors

is

It has been reported that IgA deficiency

phenytoin therapy appears to be genetically

determined and linked to the HLA-A2 antigen (Gilhus eta!, 1982c; Aarli
and

Gilhus,

1983).

Also,

various

immune alterations in epileptic
HLA-A2

antigen. has

immunoglobulin
has

an

1978).

HLA antigens are associated with

patients

and

with

epilepsy

been linked to decreased IgG titers

itself:

and

altered

subclasses (Fontana eta!, 1978b) while HLA-87

antigen

increased frequency among epileptic patients (Smeraldi et a!,
The current study has shown a depressed NK activity and a low

OKT4+/ 0KT8+ ratio in both epileptic children and their siblings.
it would

appear that these immune system abnormalities

also

Thus,
have

a

genetic basis.
The

question of which

factors

epileptic patients remains a complex one.

cause

immune alterations

in

There is evidence for drug

effects and disease effects: that is immune alterations may result from
disease

processes or conversely,

epilepsy

in some cases may be a

result of an immune abnormality such as autoimmunity. It is interesting
that various

types of autoantibod ies have been found

in

epileptic

patients: anti - nuclear (Chiu eta!, 1982), anti-mitochondrial (Anderson
and Moskilde, 1977), anti-muscle and anti-brain nicotinic acetylcholine
receptor (Fontana eta!,

1978a), and brain autoantigens (Popova eta!,
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It has been suggested that AED may activate a latent autoimmune

1975).

response (Alarcon-Segovia eta!,
to

be

lupus

1972) and various AED are considered

erythematosis-activating drugs

(Alarcon-Segovia

and

Fishbein, 1975).
This study
found

in

has demonstrated immune alterations

epileptic patients.

Further,

not

previously

evidence indicated that the

depressed NK function and low OKT4+/0KT8+ ratios in epileptic patients
is

likely

epilepsy

not caused by either AED therapy or disease
but

indicate the

rather may be genetically determined.
importance of appropiate control

studies of epileptic patients:
and

unrelated

patients.

These

subjects

both family members,

results

in

immune

such as siblings,

age- and sex -matched control subjects are necessary

order to properly interpret observations .
further

processes of

Such studies would

light on the basis of immune abnormalities seen

in

in
shed

epileptic
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CHAPTER IV
EFFECTS OF PHENYTOIN AND CARBAMAZEPINE ON
NATURAL KILLER CELL ACTIVITY
IN VITRO
Introduction
Natural

killer (NK) cells are a subpopulation of

lymphoid

with the innate ability to recognize certain target cells as

cells

abnormal

and mount a cytotoxic attack against these target cells resulting
their lysis.

Killer (K) cells are also contained within the

population and are responsible for antibody-dependent,
mediated killing.

in

lymphoid

non-complement

The activities of both cells reside predominantly in

the large granular lymphocyte fraction.

Their activities are thought

to

immunosurveillance

be

important

in

host defense

and

based on

evidence in both human subjects and experimental animals.
Phenytoin and carbamazepine,
(AED),
In

widely

used

antiepileptic drugs

have been associated with immune function alterations in man.

particular,

phenytoin has been found to depress IgA level s (Yabuki

and Nakaya, 1976; Martinez-Cairo et al, 1980), specific antibody titers
and cell

mediated reactions

(Sorrel

et

al,

1971).

More

severe

reactions to this drug include complex immunodeficiencies (Masi et al,
1976), agranulocytosis (Tsan et al, 1976) possibly autoimmune in nature
(Taetle et al, 1979), lymphadenopathies (Bellido et al, 1977 ), lymphoma
(Lukes and Tindle, 1975), and a multitude of hypersensitivity reactions
(Booker,

1975; Haruda, 1979).

Carbamazepine has also been linked with

agranulocytosis (Luchins, 1984), neutropenia, and leukopenia (Cereghino
et al, 1974; Hart and Easton, 1981).
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There appears to be a different individual susceptibility to the
immunosuppressive effects of AED (Massimo et a!,

1976).

Evidence is

emerging that these drugs do have many effects on the

immune system,

particularly phenytoin,

This investiga-

as shown in clinical studies.

tion studied the effects of two AED on killer cell activities.
Materials and

~

Freshly drawn
volunteers.

blood was

Peripheral blood mononuclear cells

obtained from
(PBt~C)

healthy

were obtained by

centrifuging whole blood on a Ficoll-Hypaque density gradient.
were then
Island,

rinsed and suspended in

RPMI-1640 medium

(GIBCO,

New York) containing penicillin (100 units/ml),

(100 mcg/ml), and

1~ %

PBMC
Grand

streptomycin

fetal bovine serum (Hyclone Laboratories, Logan,

UT).

Phenytoin

Chemicals.
Lambert Co.
pH

11

(powder) was a gift from Parke-Davis Warner-

(Ann Arbor,

with

4N NaOH

Ml).

and diluted

appropiate concentrations .
Sigma Chemical

Co.

Phenytoin was dissolved in 0.9% NaCI at

(St.

with

RPMI-1640

medium to the

Carbamazepine (powder) was obtained from
Louis,

(Sargent Welch Scientific Co .,

MO),

dissolved in propylene glycol

Skokie IL),

and diluted with RPMI-1640

medium.
Experimental

protocol.

Three concentrat ions

of phenytoin and

carbamazepine chosen for this study were representative of levels
clinically.

Plasma concentrations of 10-20 ug/ml phenytoin and 8 ug/ml

carbamazepine were considered therapeutic levels.
and

used

carbamazepine of 40 and 10-16 ug/ml,

Levels of phenytoin

respectively,

were

in the

range considered acutely toxic:
nystagmus

and

50
central nervo us system effects such as

ataxia become apparent in patients with

plasma

levels

near or above these concentrations (Rail and Schleifer, 1980).
PBMC were pre-incubated for 20 hr in either supplemented medium
alone or medium with drug.

The cells were rinsed and

resuspended in

medium with or without drug present followed by assessment of

natural

killer cell activity.
Natural

killer cell assay.

This assay \vas carried out as described

in the methods section of Chapter III.
Interferon ore-treatment.

PBMC were pre-incubated with either 500 or

250 units/ml human alpha-interferon (Sigma) 18 hr prior to the NK cell
assay.

The PBMC were then rinsed and resuspended in medium followed by

assessment of NK cell activity.
Antibody-deoendent cell-mediated cytotoxicity (ADCC)

~-

This

assay was carried out as described in the methods section of chapter
I I I.

Statistical

Data were analyzed with ANOVA and the

analysis.

significant difference test,

with a 95% confidence interval

least
for

a

normal distribution.
Results
Phenytoin and ]K

~

activity.

Phenytoin in concentrations of 40,

20, and 10 ug/ml suppressed NK cell activity in a dose-dependent manner
in vitro (Figure IV-1,

p

<

0.001).

Phenytoin did not appear to alter

lymphocyte viability since cells incubated for 24 hr in concentrations
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12:1
25:1
Effector to Target Cell Ratio

Peripl1eral blood mononuclear cells were pre-incubated

with phenytoin and assessed for natural killer cell activity in the
presence of 0

IZZd,

10 -

, 20

l'§J,

and 40

CJ ug/ml

Natural killer cell activity is expressed as mean percent

of phenytoin.
51

cr release

and standard error of the mean at various ratios of effector to target
cells: 50:1, 25:1, 12:1 and

6:1.

Phenytoin at each concentration

significantly depressed 51 cr release (p < 0.05).

of phenytoin up to 40 ug/ml had the same viability as
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diluent-treated

cells as shown by trypan blue exclusi on (98.0%, data not shown).
PBMC pre-incubated for 20 hr with concentrations of phenytoin
to 40 ug/ml,
effected

rinsed several times,

up

and suspended in drug-free medium

NK cell cytotoxicity at levels not

significantly different

from that of diluent-treated PBMC (Table IV-1) .
Carbamazepine and NK cell activity.

The drug carbamazepine

variable effect on NK ce ll activity (Figure IV-2 ).

had

a

PBMC treated with 8

ug / ml

carbamazepine had a slightly depressed

activity

with

diluent-treated cells though this decrease was not

as

compared

significant.

Treatment o.f cells with 10 ug/ml resulted in a significant

increase in

activity as compared to cells treated with 8 or 16 ug/ml (p

<

0.05).

but variable effect on

NK cell

Carbamazepine may

have

a slight

cytotoxicity depending upon its concentration.
Propylene~

and NK_ cell activity.

A comparison of the NK cell

activity from PBMC treated with the st andard medium diluent control for
phenytoin

which

contains

sa line and

RPMI-1640 with

that

for

carbamazepine, which has a 1.4% final concentration of propylene glycol
in RPMI-1640,
the

indicated a significant depression of activity caused by

propylene glycol (Figure IV-3,

p< 0.001).

In another series of

experiments it was found that propylene glycol concentrations as low as
0.1% v/v depressed NK cell activity of PBMC (data not shown).
Phenytoin ..2.!JQ_ interferon.

Because of the

pronounced effect of

phenytoin on NK cell activity,

it was of interest to investigate the

effect of th is drug on the abil ity of alpha-interferon to augment

NK
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TABLE !V-1
PHENYTOIN AND NATURAL KILLER CELL ACTIVITYa
Release at effector to target cell ratio
12:1

6:1

Diluent

28.2
9.7

20.3
B.O

10 ug / ml +/ +b

24.1
5.8

16.2
6.8

20 ug / ml +/+

21.1
6.7

12.4
5.0

40 ug / ml . +/+

9.5
4.1

2.6
2.9

10 ug/ml +1-c

27 . 3
9.7

19.6
8. 7

20 ug/ml +I-

30.0
8 .4

20.6
10.1

40 ug / ml +I-

29.5
12.6

21.6
10 .8

Treatment

a.

Human peripheral blood mononu c l ear cells were assess ed f or natural

killer ce ll activity following incubation with phenytoin.

Activity is

expressed as mean percent chromium release and standard deviation at
the effector to target cell ratios indicated: N=4 for all means.
b.

Phenytoin, included in both the pre-incubation and in assay of

peripheral blood mononuclear cells, significantly depress ed natural
killer cell activity (p < 0.001).
c.

Phenytoin, included in the pre-incubation of peripheral

blood

mononuclear cells but not in the assay, did not depress natural killer
ce ll activity comp ared to ce lls treated with diluent only.
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FIGURE IV-2 .

Peripheral blood mononuclear cells were pre-incubated

with carbamazepine and assessed for natural killer cell activity in the
presence

of 0

carbamazepine.
percent

51

EZZ!, 8

-

,

10

C§l, and 16 D u g / ml

of

Natural ki 11 er cell activity is expressed as mean

Cr release and standard error of the mean at various ratios

of effector to target cells : 50:1, 25:1, 12:1, and 6:1.
had no significant effect on mea n percent

51

Cr release.

Carbamazepine
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FIGURE IV-3. Peripheral blood mononuclear cells were pre-incubated with
propylene glycol and assessed for natural killer cell activity in the
presence of medium alone ~or 1.4% v/v concentration of propylene
glycol -

· Natural killer cell activity is expressed as mean percent

51 cr release and standard error of the mean at various ratios of
effector to target cells:
significantly depressed

50:1, 25:1, 12:1 and 6:1.

51

cr release (p < 0.001).

Propylene glycol

cel l cytotoxicity .

PBMC were

interferon/ml and phenytoin,
in the presence of drug.
to respond
did

incubated

with
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alpha-

250 units

rinsed, and assessed for NK cel l activity
Phenytoin did not block the ability of PBMC

to interferon at any of the

phenytoin concentrations

but

depress NK activity in a dose-dependent manner (Figure IV-4,

0.001).

The pattern of phenytoin-induced depression of

treated cel l s was simi liar t o that seen with PBMC
interferon.

Simi liar

p

<

interferon-

not treated

with

results were found when PBMC were incubated

in

500 units of interferon/mi.
Phenytoin

and ADCC.

Phenytoin also inhibited ADCC

dependent fashion (Figure IV-5, p < 0.001 ).

in

a dose-

However, the depression of

thi s act ivity occurred only at phenytoin concentrations of 20 and

40

ug/ml and not at 10 ug/ml as seen with NK cell killing.
Discus sion
In

the current study,

phenytoin depressed basal and

interferon-

NK cel l cytotoxicity in a dose-dependent manner

augmented

in

vitro.

This depression appeared reversible since PBMC incubated wi th phenytoin
and

resuspended in medium without drug showed normal

pattern of

inhibition of

interferon

and

indicating

that

NK cell

activity

inhibition resu lts from the ability of

caused

augmentation .

In fact,

with
same,

phenytoin

to

and not mechanisms

of

a comparison of the depression

by phenytoin with or without i nterfero n pre-treatment

suggests

that interferon may act in an antagonistic fashion to phenytoin .
example,

The

PBMC treated

those not treated with interferon appea'red the

interfere with the basal cytotoxic mecha nisms
interferon

of

activities.

at the effector to target cel l ratio of 6:1,

For

interferon
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40
10
20
Treatment, ug/ml Phenytoin

Peripheral blood mononuclear cells Vlere pre-incubated

with phenytoin

and 250 Units alpha interferon/ml and assessed for

natural killer cell activity in the presence of 0, 10, 20 , and 40
ug/ml of phenytoin. Natural killer cell activity is expressed as mean
51
percent
cr release and standard error of the mean at various ratios
of effector to target cells and pre-incubation with and without
interferon:

12:1 + interferon

interferon

e ,

•

, 12:1 - interferon

0

and 6:1 - interferon

concentration significantly depressed
treated and untreated cells (p < 0.05).

51

0 ,

Phenytoin

cr release of

6:1 +

at each

interferon
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FIGURE IV-5 .

Pe ripher a l blood mononuclear cel ls were pre-incubated

with phenytoin and assessed for antibody-dependent cell-mediated
cytotoxicity

in

the

presence of 0

rzzl ,

10 -

, 20

~, and

40CJ ug/ml of phenytoin. Antibody-dependent cell-media ted cyto51
toxicity is expressed as mean percent · cr release and standard error
of the mean at various ratios of effector to target ce lls : 25 : 1, 12:1
and 6:1.

Phenytoin at 20 and 40 ug / ml conce ntration significantly

51
c r release (p < 0.05) .
depressed

stimulated control and phenytoin-treated,
248%,

respectively.

However,
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cells by 139% and

40 ug/ml,

additional

work would be needed to

confirm this effect.
The present study shows a pronounced phenytoin-induced depression
of NK cell activity by PBMC isolated from healthy donors and so is
short-term assessment of phenytoin's effect on

this

activity.

a

This

depression was found at concentrations of phenytoin representing plasma
levels considered to be therapeutic to neurotoxic in range.

The long-

term effect of phenytoin on NK cel l s is unknown and is presently being
investigated using an in vivo animal model.
NK cells are thought to play a vital role in host defense and to
be a first line of defense against developing neoplasms.

Evidence to

support these roles have been found in both man and animals (Herberman,
1984).

This effect of phenytoin on NK cell mediated cytotoxicity

interesting

in

light of the association

including phenytoin,
There are numerous

of

hydantoin medications,

with lymphoproliferative disorders and lymphoma.
reports

of

patients on

long-term

hydantoi n

treatment who have developed these disorders (Lukes and Tindle,
and

a 10-fold

epileptic

is

increase

in the expected

incidence of

patients on hydantoin therapy has been

1975)

lymphoma

reported

in

(Anthony,

1970).
The mechanism
presently

by which phenytoin depresses NK cell

activity

unknown. · Phenytoin may alter the binding of the effector

cell

to its target and/or inhibit the ability of the effector cell

lyse

its target once a conjugate is formed.

these

is

requires

investigation.

a single cell

assay

To distinguish

which

is

currently

to

between
under
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One theory on the mechanism by which phenyto in suppresses seizure

activity

is by alteration of Ca++ fluxes and Ca++ dependent processes

(Greenberg eta!,
Harris,
a!,

1984 ; Sugaya eta!,

1984 and 1985;

Ca ldwell

and

1985) and by inhibition of Ca++ release from stores (Sugaya et

1985) .

Ca++ and the calcium-binding protein calmodulin have been

shown

to be important in NK ce ll cytolysis (Rochette-Egly and Tovey,

1984)

and phenytoi n may depress NK cell act ivity by altering Ca++

f l uxes

across cell membranes orCa++ binding prot eins .

The abi li ty of

interferon to augment NK cell act i vity is al so dependent upon movements
of Ca++ and t he presence of calmodul in.
interferon-induced

NK ce ll lysis,

Phenytoin depressed basal

and

thus phenytoi n may depress NK ce ll

activity via its effect on Ca++ and its effector proteins.

Delorenzo

(1982) has indi cated that phenytoin inhibits the Ca++-calmodulin kinase
system but not ca lmodulin itself.

Thu s the effects of

Ca++ and Ca++-binding prote ins are unclear.

phenyto in on

It is conce ivable that

phenytoin alters NK ce ll activity by altering Ca++ channelling and Ca++
mediated events either directly such as by inhibition of ca lmodulin
indirect ly such as through
protein s after theCa++ sig nal,

decreased

phosphorylati on

of

or

spec ific

as has been shown in synapt ic vesicles

(Delorenzo, 1980).
Phenytoin also depressed ADCC but only at the 2 higher concentrations

studied.

population

Large granular lymphocytes contained within the PBMC

ha ve been shown to be capable of both NK cel l cytotoxicity

and ADCC (Bradley and Bonavida, 1982) al though by a differe nt mechanism
(Koren and Williams,
step though
1985),

1978) .

Killing by either cell type is a multi-

il l-defined process,

involving lyt ic

granu les

react i ve oxygen intermediates (Sutha nt hiran eta!,

(Podack,

1984),

and

outward
It
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1985).

K+ currents during the lethal hit stage (Chandy eta!,

is possible that phenytoin depresses both NK cell killing and

by the

same mechanism:

that is other pharmacologic agents have

shown to depress both activities (Henney

and

Gillis,

1984).

ADCC
been
This

that some steps may be shared in the mechanism of these two

indicates

types of killing.
It is reasonable to assume that depression of NK cell activity by
phenytoin can

result

Diethylstilbestrol,
tically

in man,

(Kalland and
vitro

in

a synthetic

and

lymphoproliferative states.

non-steroidal agent

used therapeu-

has been found to depress NK cell activity

Haukaas,

(Kalland

lymphoma

1981) and the lytic phase of this

and Campbell,

1984).

in

killing

vivo
in

There is a clear association

between

in utero exposure to diethylstilbestrol and the development of

vaginal

and uterine cancer (Mclachlan and

Dixon,

1976).

Ultraviolet

radiation has also been found to suppress the post-binding lethal stage
of NK cell cytolysis and ADCC (Weitzen and Bonavida, 1984).
Various
aberrations
(Kulkarni

studies
(Herna

et

Furthermore,
micronucleated

a!,

suggest that phenytoin

and Obe,
1984)

by

and

causes

chromosomal

sister-chromatid exchanges

in humans exposed to this

drug

long-term.

De Oca-Luna eta! (1984) found a significant increase in
polychromatic erythrocytes in mice exposed to multiple

injections of phenytoin,
shown

1977)

an indication of chromosomal aberrations

nuclear fragments.

development of neoplasms:

Phenytoin may then act two ways in

by a direct or genotoxic mechanism and

as
the
by

immunosuppression, an epigenetic mechanism.
Phenytoin has also been found to. depress mixed lymphocyte reaction
in

vitro (Bluming eta!,

1976) and alter lymphocyte blastogenesis to

mitogens
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Thus, there may be a variety of

(Neuwelt et a!, 1983 ).

mechanisms

by which phenytoin causes immune

abnormalities,

possibly

leading to immunodeficiencies on the one hand and lymphoma and
proliferative

states on the other.

important for

immunbsurveillance,

NK cells,

are thought to

combating viral infections (Herberman,

1982) and in

as

well
be

depression of

as

being

important

in

immunoregulation,

such as through the production of lymphokines (Scala eta!,
a result,

!ympho-

1984).

As

NK cell activity by phenytoin cou ld lead to a

variety of immune system alterations.
Carbamazepine did not sign ificantly depress NK cell activity from
diluent -treated cells
concentration.
biologically

and

Thi s effect was not dramatic
insignificant.

Ca++-dependent

s li ghtly increased activity at
however,

10 ug/ml

and may

Carbamazepine has been found to

phosphorylation of synaptosoma l proteins

be

depress

s imilar to

phenytoin but at much greater concentrations than found therapeutically
(Delorenzo,

1980).

It is interesting that phenytoin and carbamazepine

are useful in contro lling s imiliar seizure types and have considerable
over lap

in their 3 dimensional structures (Rail and Sch leifer,

1980),

yet are dissimilar in their effects on NK cell activity.
Propylene glycol depressed

This effect should be kept in mind with its use as a diluent

manner.
for

drugs

found
ability

NK cell activity in a dose-dependent

in immu no logical assays.

Ethylene glycol has

to depress NK cell activity in vitro;

also

presumably due to

been
its

to act as a hydroxyl radical scavenger (Suthanthiran et a!,

1984).

Due to

propylene glycol
mechanism.

its

structura l

probably

simi larities to ethylene glyco l ,

depresses NK ce ll activity by this

same
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CHAPTER V
EFFECT OF

PHENYTOIN ON ANTIBODY

PRODUCTION:

USE OF A

MURINE MODEL
Introduction
Phenytoin,

a widely used antiepileptic drug (AED), has been found

to alter both humoral and cellular immunity in man.

These alterations

include reduced antibody response and delayed-type sensitivity in vivo
(Sorrel eta!,
a!,

1983),

forming

1971),

and decreased blastogenic response (Neuwelt et

lymphocyte

cells

protein

synthesis, and numbers ofT rosette-

(Fontana et a!, 1978c)

from

patients treated with

interplay of drug effects,

disease processes of

phenytoin.
A complex
epilepsy,

and

genetic factors are all thought to be associated with

immune abnormalities seen in epileptic patients treated with AED.

For

example,

IgA

long-term

phenytoin

treatment

deficiency

in up to 21% of patients (Sorrel

ind icates

that

susceptibility to this

is
et

associated with
a!,

defic iency

1971):

evidence

is genetically

determined and linked to the HLA-A2 anti gen (Gi lhus eta!, 1982c; Aarli
and Gilhus,

1983).

Furthermore,

Gilhus and Aarli (1981b) found

IgA

sup pression to be more related to a history of febrile convu l sions than
to the type of epilepsy or drug therapy for some patients.
An

animal model to study effects of AED on immune function

allow a clear
system .

investigation into the effects of AED on the

Animals

(Chung and Johnson,

have

would
immune

been used successfu ll y in studies of epilepsy

1984 ; McNamara,

1984; Morishita eta!, 1984) and
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AED : for examp le in investigations of valproate-induced hepatotoxicity
(Turnbull et al,

1983; Becker and Har ris, 1983; Granneman et al, 1984;

Kesterson et al, 1984) and phenytoin-associated teratogenesis (Hicks et
a!, 1983; Watkinson and Millicovsky , 1983).

However few animal studies

have been used to investigate effects of AED on immune function.
The present report describes a murine model to study effects of
phenytoin on specific antibody production.
to

usefulness

assess other immune function

Results,

and the model's

disorders observed

in

c linical studies, are discussed.
Materj a Is
!2.!Jd9

Qllij_

Methods

and dosage levels.

Phenytoin (powder), a gift from Parke-Davis

Warner-Lambert Co.

(Ann Arbor,

11

Three dosage levels for the mice were chosen from a

with 4N NaOH.

pilot study.

MI),

was dissolved in 0.9% NaCI at pH

A low dose of 10 mg/kg (10 mg/ml) was near the dose found

to be effective in controlling electroshock seizures in other strains
of mice (Swinyard and Woodhead, 1982; Loscher and Meldrum, 1984; Zeiger
et al,
of

1983) and was considered to be a therapeutic dose.

40 mg/kg

A high dose

(40 mg/ml ) approached the neurotoxic dose 50%

in this

strain at 2 hr post injection as indicated by neurological defect.
animal

was

considered to be suffering from acute toxicity if

it was

unable to maintain balance on a rotating rod (6rpm) for 1 min in
of 3 trials
Woodhead,

at the time of peak drug effect

1982).

of acute toxicity.
Experime ntal
facility

(2

This dose was taken to represent

hr)

(Swinyard

frequent

An

each
and

periods

An intermediate dose of 20 mg/kg was also chosen.

animals.

Mice of the NFS strain were bred at our

and given food and Wftter ad libitum.

Animals 5 weeks of age
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were divided into groups using both sexes per treatment, and dosed with
phenytoin or diluent by intraperitoneal injection daily for 28 days.
Mice were injected subcutaneously with 2 mg (0.1

Immunization.

ml)

bovine serum albumin (BSA) on day 3 of diluent or phenytoin treatment
and

challenged

dissolved

in

with 1 mg on day 23 (Koller et a!,
water

at 40 mg/ml and

emulsified

1883).
1:1

BSA was

with

incomplete adjuvent (Sigma Chemical Company, St. Louis, MO).

Freund's
On day 29

the animals were lightly anaesthetized with ether and bled to determine
hematocrits,

white blood cell (WBC) counts,

and titers of antibody to

BSA.
Antibodies

Antibody measurements.
indirect

enzyme-linked

to

BSA were titered

immunosorbent assay

(ELISA).

using an
BSA at

concentration of 1 mg/ml was aliquoted into a 96-well Falcon
plate 3912 (Beckton and Dickinson and Co.,
0.1

ml/well

followed

by a 30 min

Oxnard,

incubation

at

a

Flexible

CA) in a volume of
room temperature.

Liquid was then decanted out of the wells and 0.2 ml of 1% human serum
albumin (Sigma) added to the wells as a blocking agent.
within the wells of the plate were incubated for 30 min
decanting of the liquid.
0.05 ml

at

times

with

followed

by

Mouse serum was then added in a volume of

dilutions ranging from 1/10 to

incubate for 1 hr.

The contents

1/1,000 and

allowed to

Liquid was then decanted out and the wells rinsed 3

phosphate buffered sa line (PBS).

peroxidase-conjugated goat anti-mouse IgG (Tago,

A 0.05 ml

aliquot of

Inc., Burlingame, CA)

diluted 1/1000 was added to the wells followed by 90 min of incubation.
Liquid was then decanted out,
0.05 ml

of

the

the wells rinsed 4 t imes with PBS,

substate ABTS

and

(2,2 '- azinodi - (3-ethylbenzthi azoline
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Sigma) at a concentration of 0.91mM was

sulfonic acid diammonium salt,

added. Color changes from negative control wells were read 30 min after
this with

a MicroElisa minireader (Dynatech) using a 410 nm filter.

Normal mouse serum was used as a negative control.
Statistical analysis.
and

Data were analyzed with analysis of variance

least significant difference test with the 95% confidence interval

for a normal distribution.
Results
Immunization and antibody titer.
in

decrease
alteration
both

IgG production . against BSA in mice

(Figure V-1).

This

in antibody production was significant for mice receiving

the 20

0.05).

Phenytoin induced a dose-dependent

and 40 mg/kg dose at each of 2 dilutions of serum

(p

No differences in antibody production between male and

female

mice were observed.
In general,

the animals gained or

maintained their weights during the course of the experiment with the
exception of the female mice given 40 mg/kg phenytoin.
mice

These female

lost weight during the first 2 weeks of treatment and during the

third week the mouse that had lost the most weight died.

By day 22

these mice had weights not significantly different from female mice
given diluent alone (Table V-1). Specific organ weights on the basis of
g/g

body weight for thymus,

s ignificant

spleen,

differences were

seen

and liver were variable
between

and

phenytoin-treated

no
and

diluent-treated mice (Table V-2). Grossly, no changes in the appearance
of these or other organs were seen in phenytoin-treated mice.
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40

Mice received diluent alone

IZZL3,

· 20 ~. or

or 10 -

c::=J mg/kg phenytoin for 28 days during which time they were

sensitized and chal lenged with bovine serum albumin

(BSA).

Serum

co llected on day 29 was diluted and assayed for IgG production specif i c
fo r BSA.

JgG production is expressed as a mean absorbance and standard

err or of t he mean for

serum dilutions

of

1/100 and

1/1000.

A

s ignifi cant decrease in JgG specific for BSA was found in mice given 20
and 40.,mg /kg phenyto in (p

<

0.05).
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TABLE V-1
ANIMAL WEIGHTS AND PHENYTOIN EXPOSURE
Male mice

Female mice
a

10

20

40

20.3
1.4

21.3
1.6

20.5
1.5

21.0
1.1

21.1
1.6

23.0
1.9

21.8
2. 2

21.5
1.0

23.1
1.1

24.4
2.5

22.2
2.3

21.5
0.7

19.9
2.0

24.6
1.1

26.1
2.7

22.6
2.8

22.6
1.1

20.7
1.6

25.3
1.3

26.3
2.1

22.2
1.1

23.7
1.2

10

20

40

18.6c
1.2

17.6
0.7

17.8
0.8

18.4
1.7

Day 8

19.5
1.5

19.2
0.8

18.9
0.4

17.7
1.8

Day 15

20.6
1.5

19.7
1.3

19.5
0.0

17.5
2.0

Day 22

20.9
1.1

20.7
0.8

20.3
0.4

Day 29

22.0
0.0

21.4
0.8

20.8
0.8

Treatment
b
Day 0

Diluent

Diluent

d

a.

Animals were injected daily with diluent

or phenytoin at doses of

10,

20, or 40 mg/kg for 28 days during whi ch time they were sensitized

and chal lenged with bovine serum albumin.
b.

Mean

sacrifice .

weights

at the beginning of each week and at the time of

Weights were listed separate ly for female and male mice due

to a difference in weight between the sexes .
15.

N varies from 2-4 on days 22 and 29.

c.

Standard deviation of the mean.

d.

Significantly decreased (p

<

0.05).

N=5 for days 0,

8,

and
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TABLE V-2
SPECIFIC ORGAN WEIGHTS and BLOOD VALUES
AFTER PHENYTOIN EXPOSURE
a
Treatment :
Mice per Treatment
b
Thymus Weight
Spleen Weight
Liver Weight

Diluent

10

20

40

5

7

6

8

2.44
0.45c

3.38
1.08

3.27
0.80

2.55
0.65

5.85
1.04

5.48
0.81

6.05
0.76

5.04
0.89

7.40
0.63

6.65
0.59

6.71
0.61

7.95
1.03

d

e

f
Hematocrit
g
WBC Count

46.4
2.1

46.7
2.2

47.0
1.8

43.4
4.2

10.2
6.3

16.5
10.4

20.0
10.0

13.8
13.5

a. Mice were injected daily with diluent alone or phenytoin at doses of
10,

20, or 40 mg/kg for 28 days during which time they were sensitized

and challenged with bovine serum albumin.
time of sacrifice.
treated with

Parameters studied were at

No significant differences were found between mice

phenytoin or diluent only in any of the

specific organ

weights, hematocrits, or white blood cell counts.
b. Mean thymus weights in units of g/g body weight x 10

-3

.

c. Standard deviation of the mean.
-3
d. Mean spleen weights in units of g/g body weight x 10
-2
e. Mean liver weights in units of g/g body weight x 10

f. Mean hematocrit.
3

g. Mean white blood cell count in units of leukocytes/mm blood x 10 at
time of sacrifice.
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Female mice given

40 mg/kg

had

slightly

lower

hematocrits than diluent-treated mice, although this difference was not
significant.

White blood cell counts were variable and no significant

differences were found between phenytoin- and diluent-treated

animals

(Table V-2).
Discussion
The experimental
Body weights

animals.

protocol was tolerated relatively well
were maintained or increased

by the

throughout the

injection period except for the first 2 weeks for the female mi ce given
40 mg/kg phenytoin. Specific organ weights for thymus and spleen, which
are centra I and peri ph era I lymphoid tissues,
liver,

respectively,

and for

were variable and no significant differences were found between

mice given phenytoin or diluent.
at sacr ifice.

The organs were normal in appearance

White blood cell counts and hematocrits were similiar in

mice given phenytoin or diluent.

These results suggest that phenytoin

has no overt toxicity to these particular organs and blood cel ls.
The use of this animal model appears to be suitab le for the study
of effects of AED on immune function even at high doses of drug.
have

been

Meltzer,

used to study the effects of
1984)

hydrocarbons

and

immunotoxin s such

(Wojdani eta!,

1984),

immunomodulators
as

polycyclic

(Nacy

Mice
and

aromatic

2,4-dichlorophenol (Exon et a!,

198'4), and heavy metals such as lead (Neilan eta!, 1983).
The depression by phenytoin of lgG product ion in mice against the
T-ee!! dependent antigen BSA, though not dramatic, appears to be dosedependent with
therapeutic dose.

high doses having a more pronounced effect than

the

Phenytoin is considered the AED most associated with
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immune system abnormalities in man (Aarli and Gilhus, 1983) having been
found to alter immunoglobulin levels.
are depressed

in

In particular, serum IgA levels

some patients which may lower their resistance to

infections (Gilhus and Aarli,

1981a).

However,

a predisposition

to

lgA deficiency while being treated with phenytoin on a long-

develop

term basis appears to be genetically determined (Gilhus et a!,

1982a,

Aarli and Gi lhu s, 1983).
Phenytoin

has

also been found to moderately alter

lgG and

IgM

levels (Anderson and Moseklide, 1977; Czlonkowska eta!, 1981). Fontana
et a!

(1976)

found

phenytoin therapy.

lgG4 deficiencies in

13/21

patients

receiving

Cerebrospinal fluid lgG levels have been found to

be decreased in epileptic patients given phenytoin (Fossan and
1979).

Thus,

production

the present finding of a moderate

in mice is not surprising.

reduction

cell-mediated

in

IgG

Decreased lgG production may

res ult in a depression of immune functions requiring IgG,
antibody-dependent

Aarli,

cytotoxicity by

for example

large

granular

lymphocytes and macrophage-mediated phagocytosis and killing.
It is i nteresting that offspring of pregnant mi ce given
displayed

humoral immune dysfunction as a result of prenatal

to this drug (Chapman and Roberts, 1984).
dec rea se

phenytoin
exposure

Mice showed a dose-dependent

in antibody production to pneumococcal polysaccharide,

independent antigen,

but

no changes

in cell -mediated

measured

by delayed-type hypersenstivity

allergen

oxazo lone.

These

results

that

challenge to

sheep

contact

phenytoin given

prenatally can adversely affect the normal deve lopment and
of humoral immune function.

immunities

response to the

suggest

a T-

expression

Levo (1982) noted a decrease in antigenic

red blood cells in

mice

exposed to phenytoin.

However,
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finding must be viewed with caution since neither data

this

nor the protocol
results
mice

used were presented in

this

report.

The above

and those presented in this report indicate the suitability of

in

studies of phenytoin on

alterations
without

immune function:

mice display

in immune function to phenytoin in ways similiar to man

the

complications and

limitations

associated with

human

studies.
The

use of a murine model to study effects of

various

AED on

immune function would be useful in investigating situations where it is
thought that an interplay of drug and constitutional factors results in
abnormalities.
et a!,

These would include altered lymphocyte numbers (Blanco

1977) and populations (Chiu et a!, 1982), immunoglobulin levels

(Fontana et a!,
(Anderson

et

receiving

a!,

Tartara et a!,

1981)

phenytoin.

potentially
has

1976;

all

1981),

of which have

Phenobarbital

has

and antibody production
been
also

seen
been

patients

shown

to be

immunosuppressive (Park and Brody, 1971) and carbamazepine

been associated with hematopoietic

and

immunologic

including neutropenia and leukopenia (Cereghino eta!,
Eastman,

in

1981).

1974;

Both drug dose effects and mechanisms

investigated using an animal model.

effects
Hart and
could

be
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CHAPTER VI
EFFECT OF PHENYTOIN ON MURINE HEPATITIS
VIRUS INFECTION AND NATURAL
KILLER CELL ACTIVITY
Introduction
Phenytoin

is

and

psychosis,
abnormalities

a widely used drug for the treatment of epilepsy,
cardiac

are

arrythmias.

associated with

A number of
use of

this

immune
drug

system

including

deficiencies resulting in increased frequency of respiratory infections
in

patients receiving phenytoin on a long-term

chronic
with

basi s .

Recurrent or

respiratory infections are especially predominant in

an lgA deficiency caused by phenyto in (Aarli and

Phenytoin

has

incidence

is

also

patients

Gilhus,

been associated with liver damage,

low and appears to be a result of a host

1983).

however the
idiosyncratic

reaction.
Few data. are available in studies of the effects of phenyto in on
other types of infections.

This investigation examined effects of

long-term phenytoin treatment on liver function and hepatitis infection
in mice.

Si nce hepati tis virus infects

and degeneration of the liver ,
indicators of infection .

hepatocytes causing

jaundice

liver function tests were

used as

Natural killer (NK) cell activity was

also

ascertained

in cells from mice given phenytoin since these cel l s are

thought to

be

important

(Herberman, 1984).

in host defense

against

viral

infection
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Materials and Methods
Phenytoin preparation and dosage levels.
prepared
V.

Phenytoin was obtained and

as described in the materials and methods section of

Dosage levels of phenytoin chosen for this study,

mg/kg,

were

considered to

10,

range from therapeutic to

Chapter

20, and 40

neurotoxic

as

described in Chapter V.
Murine hepatitis virus (MHV) preparations,
Robert

Sidwell

(Utah

State University) ,

were

a gift from

prepared from

liver

homogenates of Swiss Webster SPF mice infected with MHV (titer of
-5.6 cell

culture

infectious dose 50

percent/ml).

dose

serial

virus were made and a single (0.1 ml) intraperitoneal

given to groups of male and female NFS mice.

observed daily and their deaths recorded.
chosen

10

To determine a

suitable dose for infection into NFS mice used for this study,
dilutions of the

Dr.

The animals

were

A dilution of the virus was

for the experiments which would give a low incidence of

deaths

in infected NFS mice.
Experimental
State

protocol.

Male and female NFS mice were bred at

University and randomly assigned to 3 experimental

groups

Utah
each

with 3 mice of each sex per treatment.

Groups 1 and 3 received diluent

or phenytoin daily for 23 and 18 days,

respectively,

except on day 15
-5
when mice were injected with 0.1 ml of virus at a dilution of 10
In
group

1,

alive

on day 28 were sacrificed.

day 19,

dates of the animals deaths were recorded and animals

Group 3 animals were sacrificed on

and the livers excised, photographed, and scored for jaundice.

Serum was collected,
and

st ill

frozen,

activities of the

and lat er analyzed for bilirubin content

enzymes aspartate aminotransferase (ASAT)

and
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alanine aminotransferase (ALAT).
phenytoin for
collected,
ALAT

18 days

frozen,

levels.

Group 2 animals received diluent or

and were sacrificed on

19.

Serum was

and later analyzed for serum bilirubin,

ASAT and

Spleens were removed and a cell suspension prepared

forcing the spleens through a screen.
hypotonic

day

by

Red blood cells were removed by

shock and the cells rinsed and

resuspended

in

RPMI-1640

medium (Gibco, Grand Island, New York).
Serum bilirubin and

aminotransferase~

Serum bilirubin levels

were determined using Sigma diagnostic kit # 605-D
Briefly,

Louis,

MD) .

bilirubin in an aliquot of serum is coupled with diazotinized

sulfanili c acid
The

(St.

(p-diazobenzenesulfonic acid) to form

azobilirubin.

aliquots are then made alkal ine and read on a spectrophotometer at

600 nm.

Bilirubin standards are used to convert absorbances into mg/dl

total bilirubin.
Serum ASAT and ALAT enzyme levels were
diagnostic kit #505-0P.

determined

using Sigma

Briefly, an aliquot of serum was added to the

substrates aspartic acid and alpha-ketoglutaric acid,

or alani ne

and

alpha-ketoglutaric acid for ASAT and ALAT analysis,

respectively.

The

oxalacetic or pyruvic acid formed by ASAT and ALAT

respectively,

are

then reacted with 2,4-dinitrophenylhydrazine to form the highly colored
phenylhydrazine product.

The reaction mixture is then read spectropho-

tometrically at 490 nm.

Aminotransferase standards are used to convert

absorbances into Sigma/Fra·nkel enzyme units/ml.
Natural
in

killer~

assay.

This assay was carried out as described

the materials and methods section of chapter

III

effector splenic cells (0.1 ml) in concentrations of 100,

except that
50,

25, and

12.5

X

10

6
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cells/ml were incubated with 0.1 ml

Cr-labelled

Yac -1

murine lymphoma cells.
Stat istical

Data were analyzed with ANOVA and the least

analysis.

significant difference test with the 95% confidence

interval

for

a

normal distribution.

A virus dilution of 10

Virus.

diluent-treated mice
experiments.

and was

-5

gave a low incidence of mortality in

selected for

use

in the

phenytoin

No difference in mortality between male and female mice

was observed.

Deaths occurred on days 4-8 post virus infection.

Mice

given 40 mg/kg phenytoin (group 1) had a significantly higher mortality
rate as compared with diluent-treated mice (p< 0.05; Table VI-1).
Liver

All

appearance.

livers

from Group 3 mice were normal

in

appearance with the exception of a male mouse given 10 mg/kg phenytoin
whose liver wa s jaundiced.
Serum collected from mice in groups 2 and 3 were

Bilirubin~

analyzed

for

differences
any

assessment of li ver function.

in total bilirubin levels were found in animals

of the phenytoin doses (Table VI-2).

infected mice),
significantly

In mice of group 2,

However,

biliburin

levels

than

receiving

in group 3 (virus

animals treated with 20 and 40 mg/kg

higher

no

phenytoin

diluent-treated

had
mice.

Significantly higher bilirubin levels were found after virus infection
in mice receiving 20 and 40 mg/kg of phenytoin.
Phenytoin treatment alone did not

signicantly
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TABLE VI-1
PHENYTOIN AND MURINE HEPATITIS VIRUS INFECTION: LETHALITY
Group 1 Experimental Mice
Treatment

a

Number deaths/number animals

Death incidence
11.1%

Diluent

1/9

10 mg / kg

0/9

0.0%

w ~~~

0~

0.0%

40 mg/kg

4/ 10

40.0%

a. Male and female NFS mice were injected with diluent or 10, 20, or 40
mg/kg phenytoin for 23 days.
murine hepatitis virus.

On day 15,

all mice were infected with

Death s were recorded and death

calculated.

Mice

s ignificantly

increased mortality as compared with mice given

alone (p< 0.05).

treated

with 40 mg/kg

of

incidence was

phenytoin

had
diluent
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TABLE VI-2
PHENYTOIN AND MURINE HEPATITIS VIRUS INFECTION :
SERUM BILIRUBIN LEVELS
a

Group 2
- MHV
b
2.31c
0.46

2.12
1.90

10 mg /kg

1.95
0.23

2.19
0.67

20 mg/kg

2.03
0.54

2.35
0.55

40 mg/kg

2.41
1. 95

4.19
0.30

Treatment
Diluent

Group 3

+ MHV

a. Male and female NFS mi ce were injected with diluent or 10, 20, or 40
mg/kg

phenytoin for 18 days.

On day 15,

al l mice in group

3 were

infected with murine hepatitis virus (MHV). All animals were sacrificed
on day 19.

Total serum bilirubin levels were determined spectrophoto-

metrically and expressed as mg /dl .
bilirubin

leve ls

increased

bilirubin levels in mice given 20 and 40 mg/kg phenytoin

<0.05) .

(Group 2 mice).

Phenytoin alone did not alter serum
Virus

infection

significantly
(p

Sign ificant increases in bilirubin leve l s were also fo und in

MHV-infected mice given

20 and 40 mg/kg phenytoin as compa red with

infected mice injected with diluent only {p < 0.05, Group 3 mice).
b. Mean, N=6.
c. Sta ndard deviation.
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alter serum ALAT levels (Table Vl-3 , group 2), however a comparison of
animals in group 3 showed a signi f icant increase in ALAT levels in mice
receiving the diluent,
infection.
10 mg/kg
treated

10,

and 20 mg/kg

phenytoin after virus

In these virus-infected mice of group 3, mice treated with
phenytoin had significantly higher ALAT levels while those

with 40 mg/kg phenytoin had signficantly

lower

levels

than

diluent-treated animals.
Phenytoin treatment al one did not si gnificantly
alter serum ASAT levels in mice trea t ed with virus or not.
trend toward increased level s were found
40 mg/kg
treatments:

phenytoin

showed

However,

a

except that mice treated with

lower ASAT levels

than mice

in

other

this difference was s ignificant in mice not treated with

viru s (Table V1-4, p < 0.05).
Natural killer
mice was

U!!0 ftll activity.

NK cell activity of group 2 male

reduced in a dose-dependent manner in mice given

phenytoin.

Thi s depression was significant in male mice given 40 mg / kg (Figure VI1,

p< 0.05).

Female mice in all t reatments had significantly

lower

activity than male mice and much variation was observed (p < 0.01).

No

significant differences in NK cell activity were found in female mice
given phenytoin (Figure VI-2).
Discussion
The effects of phenytoin on l iver function and
were

virus

infection

investigated with an animal model used to study the effects of

immunomodulators on
phenytoin

has

virus infection (Sidwell

et

al,

1977).

not been associated with direct drug-induced

Since
hepato-
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TABLE VI-3
PHENYTOIN AND MURINE HEPATITIS VIRUS INFECTION:
SERUM ALANINE AMINOTRANSFERASE LEVELS
Treatment

a
Group 2
- MHV

Group 3
+ MHV

b

Diluent

43.1 c
3.0

75.2
32.7

10 mg/kg

45.3
6.6

114.1
78.9

20 mg/kg

52.0
8.7

71.8
16.5

40 mg/kg

48.2
8.6

47.9
25.3

a. Male and female NFS mice were injected with diluent or 10, 20, or 40
mg/kg

phenytoin for 18 days.

On day 15,

all mice in group

3 were

infected with murine hepatitis virus (MHV). All animals were sacrificed
on day

19.

determined
units /m i.
Virus

Serum alanine aminotransferase
spectrophotometrically and

{ALAT)

levels

expressed as

were

Sigma/Frankel

Phenytoin alone did not alter ALAT levels (Group 2 mice).

infection significantly

increased ALAT levels

in mice given

diluent, or 10 and 20 mg/kg phenytoin {p< 0.05). Significant increases
in ALAT

levels were found in infected mice (Group 2) given

phenytoin as compared to

mice treated with diluent only

Mice given 40 mg/kg of phenytoin showed depressed levels.
b. Mean, N=6.
c. Standard deviation.

10 mg/kg
{p < 0.05).
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TABLE VI-4
PHENYTOIN AND MURINE HEPATITIS VIRUS INFECTION:
SERUM ASPARTIC AMINOTRANSFERASE LEVELS
Treatment

a
Group 2
- MHV

Group 3
MHV

+

b

Diluent

130.9c
25.3

149.7
34.0

10 mg/kg

149.8
30.2

164.3
72.8

20 mg / kg

148.3
19.2

173.5
71.2

40 mg/kg

85.7
18.6

120.2
25.2

a. Male and female NFS mice were injected with diluent or 10, 20 , or 40
mg/kg phenytoin for 18 days.
infected with murine
ficed on day 19.
determined

On day 15,

all mice in group

hepatiti s virus (MHV).

3 were

All animals were sacri-

Serum aspartic aminotransferase (ASAT) levels were

spectrophotometrically and

expressed

units / ml (mean of 6 mice and standard deviation).

as

Sigma/Frankel

Phenytoin alone did

not alter ASAT levels (Group 2 mice ). ASAT levels increased slightly in
mice

infected with virus.

Mice given 40 mg/kg phenytoin had low ASAT

levels which were significant in mice not treated with virus (p< 0.05).
b. Mean, N=6.
c. Standard deviation.

82

Q)

Ul

0

40

Q)

a;
0::

E

.E:J

30

0

'.r:.
u

c

Q)

20

~

Q)

a.

c
0

Q)

10

~

100:1

50:1

25:1

12:1

Effector to Target Cell Ratio

FIGURE Vl-1

Splenic cells were isolated from male mice treated with

D

diluent

t2ZJ,

for

killer

activity.
Na tural
51
(NK) cell activity is expressed as a mean percent Cr release

(N=3)

and standard error of the mean at var ious ratios of effector to

or 10 •

•

20 C§J, or 40

mg/kg phenytoin

18 days and assessed for natural killer cell

target ce ll s.

A significant decrease in mean releases were effected

by mice treated with 40 mg/kg phenytoin (p

<

.05 ).
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100:1

25:1
50:1
Effector to Target Cell Ratio

FIGURE VI -2 Splenic cells were isolated from female mice treated with

diluent ~. or 10 •

•

zocss:J.

phenytoin for

or 400mg/kg

18 days and assessed for natural killer cell activity.

Natural

killer

51

(NK)
and

cell activity is expressed as a mean percent

Cr release

(N=3)

standard error of the mean at various ratios of effector to target

ce II s·.

A significant decrease in mean releases

were effected by

female mice as compared with male mice in all 4 treatments (p < 0.001).
Phen ytoin treatment had no effect on NK cell activity in female mice.

toxicity,
ascertained
Jaundice

84
Liver fu ncti on was

MHV was chosen as the infectious agent.

by measuring bilirubin and ALAT and ASAT levels in

serum.

and degeneration of t he liver caused by MHV infection results

in an increase in total bilirubin levels in blood due to impairment of
liver metabolism and excretion of conjugated products into
increase

bile.

in the liver enzymes ALAT and ASAT in blood after

An

infection

are due to leakage of these enzymes following hepatocyte degeneration
and loss of membrane integrity.

Animals in group 3 were sacrificed at

an ear ly stage of infection to prevent deaths in these mice.
A high dose of phenytoin (40 mg/kg) caused a significant
in mortality

from MHV infection.

serum bilirubin,
in

Phenytoin alone did not not alter

ALAT or ASAT levels:

virus -infected animals.

virus

increase

t hes e levels generaly increased

Increase in bilirubin

infection was most notable in mice given

level s following

40 mg/kg

phenytoin.

Serum ALAT levels were higher from infected mice given 10 and 20 mg/kg
phenytoin,

but lower in mice given 40 mg/kg.

Serum ASAT levels in the

latter mice were low in comparison to mice in other treatments with or
without virus infection.
Since the mortality and bilirubin data indicate an

increase

susceptibi lity to MHV infecti on caused by high doses of phenytoin,
low ALAT and ASAT
However,

level s in the serum of these mice

the

puzzling.

high levels of phenytoin in the serum may be interfering with

the aminotransferase assay,
high

is

in

phenytoin

possibly by inhibiting these enzymes.

levels inhibit am inotransferase activities

intermediary metabolism by the li ver may be altered.
been associated with

height and weight

abnormalities

in

Phenytoin
in

If
vi vo,
ha s

children

(Trimble and Corbett, 1983) and interference with transaminase activity
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could

potentially alter protein m·etabolism sufficiently to depress

growth.
A dose-dependent depression of NK cell activity by phenytoin was
found

in male mice and was significant in mice treated with 40 mg/kg.

Phenytoin
manner,
cells

has been found to depress,

in a dose-dependent,

reversible

both basal and interferon-augmented NK cell activity of
in vitro

(Results,

Chapter IV).

human

The results presented

indicate a long-term effect of phenytoin on NK cell-mediated
Female mice had variable and

activities

found in female mice may not be as

depression as higher activities in male mice.
animals
and

lysis.

significant ly lower NK cell activity than

male mice and phenytoin treatment did not alter this activity.
NK cell

here

The low

sensitive to

A larger number of

.pa

might be necessary to examine NK cell activity in female mice

its modulation by phenytoin.

affect NK cell activity,

It is possible that female hormones

and the phasic nature of these hormones could
is

no

The depression of NK ce ll activity by high doses of phenytoin

in

increase variation

in

NK cel l

activity.

However,

there

information available on this topic.

mice may contribute to the increased deaths found after MHV infection.
However,

both male and female mice appear to have the same increase in

mortality even though no evidence for NK cell depression by
phenytoin was found in female mice.
function
that

Thus phenytoin may depress immune

in other ways besides NK cell activity.

interferon augmented

phenytoin
Interferons

NK cell

activity may

in vivo as has been found in vitro
are

long-term

Jymphokines with antiv iral

One possibility

is

be depressed

by

(Results,
properties.

Chapter

Effects of

phenytoin on cytotoxic T-ee!! (T ) mediated lysis are unknown:

c

IV).

these

cells are also important in host defense against vi ral infection.
phenytoin alters T activity,

c
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If

this may also contr i bute to a decreased

resistance to MHV or other viral infections .
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CHAPTER VII
CONCLUSIONS
Clinical Studies
A number of
patients.

immune abnormali t ies have been found

in epileptic

Several but not all of these defects appear to be related to

the toxic effects of antiseizure medications.
basis of

immune abnormalities in epilepsy,

subsets of

In order to examine the
various

populations

peripheral blood mononuclear cells (PBMC) from

patients and
investigated.

their s iblings were enumerated

and

and

epileptic

their functions

Significantly reduced natural killer cell (NK) activity

was found in cells isolated from epi leptic patients and their siblings.
A decreased
patients.

ratio of OKT4+ /OKT8+ ce lls was also found

Enumeration of the

PBMC

showed

in

epileptic

a significantly

lower

proportion of Leu 11+ cells in the patients which may account for the
low

NK activity found.

Antibody-dependent cell-mediated cytotoxicity

(killer)

activity was

simi li ar

in patients

and

control

Patient

blastogenic responses to the T-cell mitogens

subjects.

concanavalin A

and phytohemagglutinin and to the B-cell mitogen pokeweed mitogen were
variable and

no significant differences were

found.

forming

cells of the patients were within the

results

indicate

alterations

seen

Total

normal

range.

possible genetic basis for some of the
in epileptic patients and suggest

that

rosetteThe
immune

appropriate

contro l subjects in immune studies of epileptic patients should include
close

relatives of the patients as well as . .unrelated control

for correct interpretation of experimental observat ions.

subjects
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ln.. Vitro Studies
Several
found

to

alter

alterations
severe
In

of the widely used antiepileptic drugs (AED)

in

immune function in man.

Effects

states and
natural

immunoglobulin levels and antibody production to more

phenytoin has been associated
lymphoma.

killer

(NK)

with

agranulocytosis.

lymphoproliferative

In the present paper effects of phenytoin on
and

cytotoxic ity or ADCC)

killer

(antibody-dependent

cell activity were

cell-mediated

investigated.

depressed NK cell activity in a dose-dependent manner in

considered therapeutic and was reversible.
interferon-augmented

cytotoxicity

suppressed ADCC

at

had

but

in

of

This
drug

Phenytoin also depressed

a dose-dependent manner and

concentrations

slightly

for suppression of NK cell activity.

a slight and

Phenytoin

vitro.

effect was observed following short -term exposure at levels

required

been

range from minor

reactions including hypogammaglobulinemia and

addition,

have

variable effect on

higher than that

The AED carbamazepine

NK cell

activity,

either

stimulating or depressing activity depending upon the concentration of
drug

that was used.

Propylene glycol,

a commonly used diluent for

drugs, also depressed NK cell activity at concentrations as low as 0.1%
v/v.
NK and killer cells are thought to be vital in host defense and a
first

line of defense against developing

their

activity

neoplasms.

by phenytoin may be a mechanism

Inhibition of

by which

develop lymphoma after long-term treatment by this drug.

patients
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In YiYQ Antibody Production
a widely used antiepileptic drug (AED), has been found

Phenytoin,

to cause immune alterations in man.
drug effects,
thought to

However,

disease processes of epilepsy,
be

a complex interplay of
and genetic factors

important in immune abnormalities

patients treated with AED.
effects of AED on

An

seen

in epileptic

animal model can be used to

immune function

without the

are

study

limitations

and

complications present in c li nical investigations. In the present study,
inbred NFS mice given phenytoin and immunized with bovine serum albumin
(BSA)

demonstrated

production.

a dose-dependent decrease

specific

lgG

The treatments were relatively well tolerated by the mice

even at high doses of phenytoin as judged by
organ weights for thymus,
and

in

hematocrits.

sp leen,

body weights,

specif ic

and liver, white blood cell counts,

Current findings in the mice indicate that phenytoin

causes alterations in immune function in ways similar to those observed
i n man.
levels

This animal model should allow investigations into toxic dose
and mechanisms by which phenytoin and other AED alter

function.

immune
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~

.Qf Phenytoin QO Murine

Hepatitis tLQLs Infection
Phenytoin,
alter

a widely used antiepileptic drug,

immune functions in man.

has been found to

In patients receiving this drug on

a

long-term basis, an increase in frequency of respiratory infections bas
been

seen,

deficiency.

particularly

in

patients

with

phenytoin-induced

Few information are available on the effects of

on other types of infections.

The present study

effects of

treatment

long-term phenytoin

hepatitis virus infection in mice.

IgA

phenytoin

investigated the

on liver function

and

A high dose of phenytoin {40 mg/kg)

significa ntly increased mortality after virus infection,

but phenytoin

alone did not alter serum bilirubin or alanine aminotransferase {ALAT)
or aspatate aminotransferase

contrast,

virus-

infected animals given either diluent or phenytoin generally

showed

increases

in serum bilirubin,

mice given

(ASAT)

levels.

ALAT and ASAT

10 or 20 mg/kg of

In

levels.

Virus-infected

phenytoin generally showed

bilirubin and ALAT and ASAT levels than di luent-treated mice,

higher
however

mice given 40 mg/kg phenytoin showed high bilirubin levels but low ALAT
and ASAT levels.
in

Since both mortality and bilirubin levels

virus -treated animals given high-dose phenytoin,

increased

this decrease

in

aminotransferase activity may be due to interference by serum phenytoin
in the assay for these enzymes, possibly 'by altering enzyme activity .
Natural

killer (NK) cell activity was significantly lower in male

mice given 40 mg/kg of phenytoin .

NK cell activity of female mice was

variable and not significantly lower in mice treated
Since

NK ce ll s are thought to

be

important

in

with phenytoin.
combating

viral
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infections, depression of NK cell activity in mice given a high dose of
phenytoin

may contribute to the decreased resistance to murine

hepatitis virus infection observed.
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